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Summary 
 
Lung cancer is one of the leading causes of death in both sex, being the second 
and third most frequent type of cancer in men and in women, respectively. The most 
frequent lung cancer type, NSCLC, is characterized by several mutations in specific 
genes, which contribute to lung cancer carcinogenesis. EGFR mutations occur in four 
different exons in about 10 % of the cases, but more frequently in exons 19 and 21, which 
are predictive of therapeutic response in NSCLC patients treated with TKI such as 
gefitinib or erlotinib. Mutations in exon 2 of the KRAS gene occur in 20-40% of NSCLC 
and occur predominantly in codons 12 and 13. ALK rearrangements with one of four 
known fusion partners (EML4, TFG, KIF5B and KLC1) are present in 1-6% of NSCLC 
tumors and are predictive of response to the TKI crizotinib.  
In a consecutive series of 207 NSCLC samples, previously analysed for EGFR 
mutations, the main goals of this study was to evaluate and compare the findings between 
fragment analysis and TaqMan SNP genotyping assay with those of the currently used 
routine methodologies, to characterize the frequency and parttern of KRAS mutations, to 
determine the frequency of ALK rearrangements and to evaluate the mutual exclusivity of 
EGFR, KRAS and ALK mutations. 
The findings show that fragment analysis and the TaqMan SNP genotyping assay 
have the same sensitivity for the most common EGFR mutations as that of the routine 
HRM amplification/DNA sequencing, which were present in 10% of the cases. Samples 
with KRAS mutations (21.7%) harbored a higher mutational frequency in codon 12 
(88.6%) than in codon 13 (11.4%). Two cases were positive for concomitant mutations in 
EGFR and KRAS. Finally, one case (0.7%) was found to have an EML4-ALK 
rearrangement. Female gender and adenocarcinoma histology were statistically 
associated with EGFR and KRAS mutations, respectively.  
This work allowed us to conclude that routine HRM amplification/DNA sequencing 
does not show any false negatives and is able to detect other EGFR mutations. The 
mutational frequency of KRAS in Portuguese NSCLC is 21.7% and in about 1% of the 
samples concomitant EGFR and KRAS mutations may occur. Finally, to identify ALK 
rearrangements, the best strategy is an initial IHC screening followed by FISH analysis.  
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Resumo 
 
O cancro do pulmão é considerado umas das principais causas de morte em 
ambos os sexos, sendo a segunda e a terceira neoplasia mais frequente nos homens e 
nas mulheres, respectivamente. O NSCLC é tipo de cancro de pulmão mais frequente, 
sendo caracterizado por várias mutações que ocorrem em genes específicos contribuindo 
para a carcinogénese pulmonar. As mutações no gene EGFR ocorrem em cerca de 10% 
dos casos em quatro exões distintos, sendo mais frequentes nos exões 19 e 21 
conferindo uma resposta terapêutica nos pacientes tratados com terapias dirigidas como 
o gefitinib e erlotinib. O exão 2 do gene KRAS apresenta uma frequência mutacional de 
20-40%, predominando nos codões 12 e 13. O rearranjo do gene ALK, com um dos seus 
quatro possíveis parceiros (EML4, TFG, KIF5B e KLC1), encontra-se presente em 1-6% 
dos casos e é preditivo de resposta ao crizotinib.  
O principal objetivo do estudo de uma série consecutiva de 207 casos, 
previamente analisados para mutações no gene EGFR, foi avaliar e comparar os 
resultados obtidos pela técnica de análise de fragementos e TaqMan SNP genotyping 
assay com os alcançados pelas metodologias utilizadas na rotina, caracterizar a 
frequência e padrão mutacional do gene KRAS, determinar a frequência de rearranjos do 
gene ALK e avaliar a exclusividade mutacional entre os genes EGFR, KRAS e ALK. 
De acordo com os resultados obtidos, as técnicas de análise de fragmentos e 
TaqMan SNP genotyping assay apresentam a mesma sensibilidade para detectar as 
mutações mais comuns do EGFR que as metodologias HRM amplification/DNA 
sequencing, e que se encontram em 10% dos casos. Amostras com mutações no KRAS 
(21.7%) apresentam uma maior frequência mutacional no codon 12 (88.6%) do que no 
codão 13 (11.4%). Dois casos apresentaram uma concomitância de mutações nos genes 
EGFR e KRAS. Por último, um único caso (0.7%) apresentou o rearranjo EML4-ALK. 
Pacientes do sexo feminino e os adenocarcinomas apresentaram uma associação 
estatisticamente significativa com as mutações no EGFR e KRAS, respectivamente. 
Este trabalho permitiu-nos concluir que os resultados obtidos pelas metodologias 
HRM amplification/DNA sequencing não apresentam nenhum falso negativo, para além 
de permitirem detectar outras mutações que ocorrem nos exões 18-21 do gene EGFR. A 
frequência mutacional do gene KRAS na população Portuguesa diagnosticada com 
NSCLC é de 21.7% e aproximadamente 1% das amostras podem apresentar 
concomitância de mutações nos genes EGFR e KRAS. Finalmente, a melhor estratégia 
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para a identificação de rearranjos do gene ALK é realizar inicialmente um screening pela 
técnica de IHC e posteriormente confirmar o resultado pela análise de FISH. 
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1. Introduction 
 
1.1 Epidemiology 
Cancer is one of the leading causes of death in developed countries after heart 
diseases (Jemal et al., 2011). Cancer is subdivided in several types that are characterized 
by their localization and tissue of origin. 
Over the years, lung cancer incidence and mortality rates underwent to some 
remarkable variations in both genders, as well as in economically developed and 
developing countries. In the last decade we have witnessed a significant decline in the 
incidence of lung cancer in men, which is reflected by a reduction in mortality rates. In 
contrast, women incidence rate started to be very low, but in the middle 70’s there was an 
exponential increase that persists until today [Figure 1]. This sudden raise of lung cancer 
cases lies in the fact that women only started to smoke several decades after men, when 
social intolerance started to disappear by mid XXth century (GLOBOCAN 2008 (IARC); 
Jemal et al., 2010). In parallel to what happens with gender, when economically 
developed countries are compared with developing countries, a similarity is noticed in the 
incidence and mortality rates of lung cancer. The elevated incidence in developing 
countries is very recent when compared to that of developed countries, so the behavior of 
incidence and mortality is very similar to what is verified in women (GLOBOCAN 2008 
(IARC); Jemal et al., 2010). Recent worldwide data classified lung cancer as the most 
common type of cancer in men with 1,095,200 new cases and as the most lethal with 
951,000 deaths (Jemal et al., 2011). In comparison, lung cancer in women is the fourth 
most common with 513,600 new cases and the second most deathly with 427,400 deaths 
(Jemal et al., 2011). 
In Europe, incidence and mortality rates of lung cancer are very similar to those 
that characterize worldwide distribution of this type of cancer. In men it is the second most 
frequent type of tumor and in women it is classified as the third more common. In terms of 
mortality it is considered one of the leading causes of death by cancer in both genders 
[Figure 2] (GLOBOCAN 2008). 
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Estimated new cases Estimated deaths 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 – US incidence and mortality rates for both sex in patients that were diagnosed 
with lung cancer between 1975 and 2009. In the past few years incidence and mortality rates in 
men describes a tendency to diminish and to stabilize (red line). However, the exact opposite is 
verified in women, since in the last decade the number of women who started to smoke has rise 
leading to an increase of incidence and mortality rates (blue line) [adapted from: 
http://seer.cancer.gov]. 
 
 
 
 
 
 
 
 
  
 
Figure 2 - Europe estimated new cases and death in both sex in 2008. In men, lung cancer is 
classified as the second most frequent type of cancer and the most lethal one. On the other hand, this 
neoplasia in women is the third more incident and the second cause of death by cancer [adapted from: 
Jemal et al., 2011]. 
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1.1.1 Risk Factors 
Risk factors are features that somehow increase the probability of developing a 
certain disease. Relatively to lung cancer, exposure to several substances has been 
related with lung cancer development. The most important is tobacco smoke that is 
characterized by a complexity of compounds that promotes alterations and damage in 
lung cells. Approximately 80% of worldwide lung cancer derives from smoking (Jemal et 
al., 2011); however, over the years a decrease in smoking habits slightly diminished the 
incidence rate of lung cancer (Molina et al., 2008). It is believed that passive smoking is 
also related with development of lung cancer and is associated with the appearance of a 
small percentage of this type of tumor (Molina et al., 2008). This association resides in the 
fact that the passive smoker is also in contact with the toxic compounds of tobacco smoke 
leading to lung cells damage. 
Exposure to radon, asbestos and other sort of environmental and occupational 
carcinogens are also related with lung neoplasia. Radon is a radioactive gas that comes 
out from rocks and dirt, which cannot be smelled, tasted or seen. For these reasons, and 
because it can infiltrate people’s houses, ordinary individuals are also a risk group. Mine 
workers are another risk group, as they have direct and daily contact with these 
substances. Prolonged exposure to occupational carcinogens like asbestos, arsenic or 
other substances enlarge the risk. The major problem of this kind of contact is the years of 
exposure (National Cancer Institute, 2011).   
The aging process increases the risk of tumor development and lung cancer is no 
exception. It is believed that people over the age of 65 are more susceptible to cancer, 
which is proved by the diagnostic age of lung cancer being mainly after 65 years of age 
(National Cancer Institute, 2011).   
Besides these four risk factors (tobacco smoke, passive smoking, exposure to 
radon or asbestos and the aging process), air pollution and susceptibility genes are also 
incorporated in the risk factors group. Air pollution is responsible for approximately 11% of 
the lung cancers that develop in urban areas (Molina et al., 2008). Susceptibility genes 
are correlated with family as well as with personal history of cancer. If an individual 
belongs to a family where the prevalence of lung cancer is accentuated, the probability of 
developing this neoplasia is slightly higher, but the risk is three times higher if it is 
associated with tobacco smoke (Molina et al., 2008). Personal history of cancer is 
associated with a higher risk of development of a second similar tumor (National Cancer 
Institute, 2011).  
It should be noted that exposure to radon or asbestos, the aging process, air 
pollution and susceptibility genes when associated with tobacco smoke increase 
exponentially the risk of developing lung cancer (National Cancer Institute, 2011).   
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1.2 Lung Anatomy and Functionality 
Lungs are one of the most important organs of our body, for the reason that they 
are the main responsible for our respiratory capacity. They are part of the respiratory 
system amongst with nose, larynx, pharynx, trachea, bronchi, alveoli and diaphragm 
(Vandam, 1952).  
Anatomically, the final part of the trachea branches in two distinct tubes, named 
bronchi, each being directed to the respective lung. Regarding to bronchi, they are 
connected with the alveoli that are disposed inside the lungs (Huber, 1949; Vandam, 
1952). In terms of partitions, the right lung and left lung have some differences in the 
number of lobes. While the right lung has three distinct lobes, the left lung only has two as 
a result of its reduced size when compared with the right one [Figure 3] (Huber, 1949). 
Both lungs are coated by two very thin layers of tissue called pleura. Between these two 
layers there is a very small quantity of pleural liquid. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 – Respiratory system anatomy. Discrimination of all organs that are included in the 
respiratory system as well as their localization in the chest cavity. It should be noted the close up of 
the alveoli structure and capillaries that involve each one of the grape-like structures [adapted from: 
www.cancer.gov]. 
 
Functionally, lungs are responsible for all the gas exchanges that are crucial to the 
survival of our organism. All gas exchanges occur in the alveoli. These tiny structures are 
disposed in a sort of a network inside the lung and are grape-like structures. The only 
function carried out by alveoli is the exchange of oxygen for carbon dioxide and vice-versa 
between the interior of lungs and the capillaries that run through the human body 
(Vandam, 1952). 
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All exchanges performed in lungs are completed in an exemplary manner as a 
result of the good function of all cells that constitute this organ. However, and similar to 
what happens in other organs, when cellular alterations occur, lungs gradually start to lose 
their full capacity. These types of alterations sometimes are related with neoplasic 
transformation of cells and can eventually culminate in the development of a tumor. 
 
1.3 Lung Cancer 
Bronchial epithelium cells, which are the base epithelium of the lung, can suffer 
specific alterations. Normally, these alterations culminate in several kinds of respiratory 
diseases, like lung cancer. As seen in a variety of cancers, the growth of lung cancer is 
also the result of a multi-step process. This is characterized by accumulation of multiple 
genetic and cellular abnormalities over time resulting in an invasive tumor (Cherneva et 
al., 2007; Massion and Carbone, 2003). 
Primary lung cancer can be classified in two distinct classes: Small Cell Lung 
Cancer (SCLC) and Non-Small Cell Lung Cancer (NSCLC) (Cherneva et al., 2007). 
NSCLC accounts for approximately 85% of all lung cancers, presenting an epithelial origin 
(Sharma et al., 2007; Sanders and Albitar, 2010), whereas the remaining 15% are 
classified has SCLC. This latter histological type presents a neural crest origin and 
responds well to chemotherapy, but commonly recurs with resistant disease (Cherneva et 
al., 2007; Sharma et al., 2007).       
 
1.3.1 Histology      
The histology of a specific cancer is related with the structure of neoplasic cells. 
Similar to what happens with other malignant tumors, NSCLC has several histological 
types that include adenocarcinomas, squamous cell carcinoma and large cell carcinoma 
(Gibbs and Thunnissen, 2001). Adenocarcinomas represent 40% of lung cancers, being 
the most common histological type (National Cancer Institute, 2011). This group is very 
heterogeneous due to the mixture of histological subtypes, such as acinar, papillary, 
bronchioloalveolar carcinoma (BAC; that is subdivided in nonmucinous, mucinous and 
indeterminate cell type), and other uncommon subtypes (Gibbs and Thunnissen, 2001; 
National Cancer Institute, 2011). Adenocarcinomas develop in the outer region of the lung 
and therefore may be present for a long time before causing symptoms. Generally, this 
histological type is more common in women, non-smokers, age below 45 years and Asian 
ethnicity. Approximately 25% of lung cancers are squamous cell carcinoma, also known 
as epidermoid carcinoma, and are closely associated with tobacco smoke when 
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compared with other histological types. As a result of its slow development and central 
localization, mostly in main bronchi, the probability of finding it in early stages is higher 
than other subcategories of NSCLC (Cherneva et al., 2007; National Cancer Institute, 
2011). This type of malignant tumor is more frequent in men than in women. Large cell 
carcinoma accounts for only 10% of lung cancers. In parallel to adenocarcinomas, large 
cell carcinomas also include a large number of different histological subtypes (National 
Cancer Institute, 2011). Normally large cell carcinomas tend to appear in the outer regions 
of the lung and are characterized by a rapid growth associated with a vast capacity to 
spread.  
 
1.3.2 Screening 
Screening methodologies, such as low-dose computed tomography (CT) scan, can 
be used to detect tumoral masses with an early stage of development, so that the 
treatment can be administrated as soon as possible. However, the absence of a stipulated 
screening methodology decreases not only the rate of survival (the 5-year survival rate is 
15%), but also the rate of cure (Molina et al., 2008; National Cancer Institute, 2011). The 
absence of defined screening methodologies is linked to the absence of benefits in high or 
low risk groups. A large number of false-positive results, increased radiation exposure and 
costs are the main barriers of lung cancer screening (U.S. Preventive Services Task 
Force, 2004). Still, the National Comprehensive Cancer Network Guidelines (Version 
2.2012) defends that certain risk groups, like tobacco smokers and individuals over the 
age of 55 years old, can be screened by CT scan, promoting a decrease in mortality in 
these risk groups (National Lung Screening Trial Research Team et al., 2011). 
 
1.3.3 Diagnosis 
Lung cancer symptoms include alterations in the respiratory system like coughing 
up blood, breathing problems, chest pain and other. When these symptoms are detected, 
and associated with the exposure or not to risk factors, it is imperative to determine if the 
alterations are associated with lung cancer or other respiratory disease (National Cancer 
Institute, 2011). 
Pulmonary neoplasia diagnosis is accomplished with blood tests allied with 
physical exams to examine the general signs of health, chest x-ray to show tumors or 
abnormal fluid in the chest, and CT scan to examine the tissue inside the chest in detail. If 
a tumoral mass is detected during the diagnosis, the characterization of the neoplasic 
cells by a pathologist is essential to determine if we are in the presence of a lung tumor. 
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This is accomplished in samples collected by a variety of techniques, like sputum 
cytology, bronchoscopy, fine-needle aspiration, thoracentesis, thoracotomy and 
mediastinoscopy. In addition to cancer diagnosis, sample collection also permits the 
histological classification of lung cancer in SCLC or NSCLC and their subtypes (National 
Cancer Institute, 2011). 
 
1.3.4 Staging 
After the preliminary diagnosis, accurate TNM Classification of Malignant Tumors 
staging of lung cancer is required and critical for adoption of the most suitable treatment 
(Molina et al., 2008). TNM classification takes into account the extension of the tumor, 
specifically if it is located in the organ of origin or if spreads to other regions of the human 
body. Usually lung cancer tends to spread to the lymph nodes, bones, liver and adrenal 
gland (National Cancer Institute, 2011). 
Staging is only possible when specific examinations, like blood tests, surgical 
evaluation, CT scan, bone scan or positron emission tomography (PET) scan, are 
performed individually or combined. CT scan of the thorax and upper abdomen is the 
most requested staging methodology, since the use of contrast can allow visualization of 
metastasis in liver, adrenal glands, brain and other organs. The main limitation of this 
technique is the lack of ability to detect microscopic metastatic disease and also to 
distinguish between mediastinal lymph nodes enlarged due to malignancy or to benign 
hyperplasia (National Cancer Institute, 2011; Molina et al., 2008). As lung cancer has the 
capacity to spread to bone, a bone scan using radioactive substances can be used to 
detect lung cancer metastases in bones (National Cancer Institute, 2011). PET scan is an 
exam with a great sensitivity, allows the visualization of the metabolic activity of malignant 
disease, and has also the ability to characterize the nodal stage of lung cancer (Molina et 
al., 2008). Nowadays cancer staging is considered a non-invasive practice, as a result of 
the association between newer technologies, such as endoscopic bronchial 
ultrasonography and esophageal ultrasonography, with PET. Therefore preoperative 
biopsies are less invasive and increase the biopsy yield (Molina et al., 2008).   
When diagnosed, approximately 50% of lung cancers are found in a metastatic 
stage (stage IV). This stage is characterized by a very poor prognosis, with 5-year survival 
rates (SR) that are less than 5% for distant disease (Rosell et al., 2009; Sanders and 
Albitar, 2010). Development of more specific, sensitive and less invasive methods for 
screening and diagnostic are crucial so lung cancer can be detected in earlier stages of 
development.  
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1.4 Lung Cancer Carcinogenesis  
Similarly to other neoplasias, NSCLC result from the accumulation of several 
alterations in different genes, related to several signaling pathways, over a long period of 
time (Knudson, 1975). Usually, gene alterations are associated with deregulation of 
several cellular mechanisms, predominantly signaling pathways involved in proliferation 
and cell growth. Once these alterations occur in bronchial epithelium, a neoplasic 
transformation takes place yielding to NSCLC (Sanders and Albitar, 2010).  
NSCLC carcinogenesis is characterized by numerous genetic abnormalities, such 
as chromosome and epigenetic alterations, gene mutations such as inactivation of specific 
tumor suppressor genes (like TP53) or activation of specific proto-oncogenes, and other 
kind of alterations that are intimately associated with tumor development [Figure 4] 
(Massion and Carbone, 2003; Cherneva et al., 2007; Sanders and Albitar, 2010). It should 
be noted that the frequency of several somatic mutations is deeply related with tumor 
histology, gender, ethnicity, age, smoking status and the development stage of the 
neoplasia (Sanders and Albitar, 2010). 
 
 
 
 
 
 
Figure 4 - Histological and molecular pathway of NSCLC. Evolution of lung carcinogenesis 
taking into account the progression of the histology of the disease and the molecular alterations 
that take place in specific stages of the carcinogenic pathway [adapted from: 
www.springerimages.com]. 
 
1.4.1 Chromosome Alterations 
Chromosome alterations in lung cancer result most commonly in copy number 
changes. In NSCLC, deletions are the most common early event, occurring mainly in the 
short arm of chromosomes three and nine (Cherneva et al., 2007; Sanders and Albitar, 
2010). Deletions of chromosome 3p are among the most common alterations in early 
stages of NSCLC development, such as pre-invasive lesions (Cherneva et al., 2007; 
Massion and Carbone, 2003). This region encodes crucial tumor suppressor genes along 
with DNA repair genes that, when inactivated, originate other cellular alterations (Knnutila 
et al., 1999). The frequency of allelic loss is higher in smokers, in the squamous cell 
carcinoma histological type, as well as in pre-invasive lesions. However, this frequency 
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tends to increase along with tumor progression, which is associated with a more 
aggressive disease (Mao et al., 1997; Wistuba et al, 2000; Massion and Carbone, 2003). 
Loss of the 3p14.2 region occurs in approximately 64% of NSCLC and is associated with 
loss of expression of the fragile histidine triad (FHIT) gene, which encodes an important 
triphosphate hydrolase responsible for apoptosis and cell cycle arrest (Sard et al., 1999; 
Garinis et al., 2001). In parallel to what happens in chromosome 3, losses in the short arm 
of chromosome 9 are also one of the earlier events that take place in NSCLC 
carcinogenesis. Locus 9p21 codifies a cyclin-dependent kinase inhibitor (p16), which is a 
tumor suppressor protein responsible for regulating the phosphorilation status of the Rb 
protein. It should be noted that 3p and 9p chromosomes deletions are not only identified in 
pre-invasive lesions, but also in normal appearing epithelium of smokers (Mao et al., 
1997; Wistuba et al., 1997).   
 
1.4.2 Epigenetic Alterations 
Functional alterations of genes can also be accomplished by epigenetic 
alterations, such as promoter hypermethylation or histone deacetylation, which are 
detectable in lung cancer (Massion and Carbone, 2003). Promoter hypermethylation is 
based on gain of methylation in unmethylated CpG islands around gene transcription start 
sites, like those of tumor suppressor genes, leading to alterations of gene expression in 
tumors (Burbee et al., 2001). Abnormal methylation can occur in the initial steps of 
carcinogenesis, inducing loss of cell cycle control, loss of mismatch repair function and 
loss of cell-cell interaction (Belinsky et al., 1998; Baylin et al., 2000). Despite the 
knowledge of the role played by promoter hypermethylation in carcinogenesis, the 
mechanism by which this epigenetic alteration may cause tumor progression is still 
unknown (Baylin and Bestor, 2002). Specifically in lung cancer, methylated loci are 
detected in tumor and also in sputum DNA, and the detection in expectoration are 
possible for up to three years before the diagnosis of cancer (Palmisano et al., 2000). 
Histone deacetylation is another epigenetic alteration that may occur during 
carcinogenesis and is associated with DNA compaction process, resulting in a 
transcriptional repression. The mechanism of histone tail acetylation is related with 
chromatin unfolding and increase of regional transcriptional activity. All this mechanism is 
performed by histone deacylases (HDACs), whose main goal is to modulate the chromatin 
structure by regulating acetylation of core histone proteins (Massion and Carbone, 2003). 
It has been noted that inhibition of HDACs promotes a decline in the level of several 
oncoproteins, what may suggest a potential role for antitumor therapeutic agents (Yu et 
al., 2002). 
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1.4.3 Genetic Alterations 
1.4.3.1 Inactivation of Tumor Suppressor Gene TP53 
Transcriptional factor p53 is a tumor suppressor protein that regulates the 
expression of several target genes, like cyclin dependent kinase (CDK) inhibitor p21 
among others (El-Deiry et al., 1994; Vogelstein et al., 2000). It is mainly a nuclear protein, 
nevertheless a small fraction has been found in the cytoplasm (Horn and Vousden, 2007). 
The main role played by this protein is stopping cell proliferation, triggered by intrinsic and 
extrinsic stress signals, so damaged DNA can be repaired, preventing mutations from 
being passed on to daughter cells (Levine et al., 2006; Horn and Vousden, 2007). 
Depending on the nature of stress signals, the role played by TP53 varies. If we are 
talking about low constitutive stress, the activation of TP53 leads to a temporary cell cycle 
arrest allowing the removal of intracellular reactive oxygen species (ROS) and repair of 
any damage that may have occurred. On the other hand, when stress induced damage is 
too severe for cell to recover, programmed cell death is initiated so cells that may have 
acquired irreparable potential oncogenic lesions can be eliminated. Activation of this 
tumor suppressor protein in early hyperplasic and pre-cancerous lesions appears to 
prevent the formation of tumors (Horn and Vousden, 2007). 
Mutations in TP53 tumor suppressor gene are one of the most frequent genetic 
alterations in human cancer, occurring in approximately 50% of all neoplasias (Massion 
and Carbone, 2003; Horn and Vousden, 2007). The most frequent mutations occur from 
exon 5 until exon 8 and are predominantly G to T transversions that result from DNA 
adducts formed by polycyclic hydrocarbons found in smokers’ lungs (Denissenko et al., 
1996; Sanders and Albitar, 2010). The TP53 mutational frequency varies according to 
lung cancer histological type, being more frequent in squamous cell carcinoma (62%) than 
in adenocarcinoma (39%) (Gao et al., 2009). It is also being implicated as predictor of 
poor prognosis, although this may differ depending of the mutated exon (Huang et al., 
1998; Skaug et al., 2000). 
 
1.4.3.2 EGFR Mutations 
Epidermal Growth Factor Receptor (EGFR) is a tyrosine kinase receptor that 
belongs to the super-family of cell-surface receptor tyrosine kinase ERBB/HER. Its main 
function is to mediate and control cell signaling by extra-cellular growth factors, namely by 
intracellular signal transduction pathways that regulate vital cellular functions like 
proliferation, angiogenesis and apoptosis (Krause and Van Etten, 2005; Sharma et al., 
2007). This super-family consists of four different types of tyrosine kinase receptors that 
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include ERBB1/HER1 (also known as EGFR) ERBB2/HER2, ERBB3/HER3 and 
ERBB4/HER4. All members have an extracellular ligand-binding domain, a 
transmembrane domain and an intracellular domain, however some dissimilarity was 
detected. The main distinction resides in the absence of a tyrosine kinase domain in 
ERBB3/HER3 and the absence of a ligand domain for growth factor ligands in 
ERBB2/HER2 [Figure 5] (Pao and Chmielecki, 2010). 
 
 
 
 
 
 
 
 
 
 
 
 
 
The receptors are spread in cell surface as inactive monomers, but when a specific 
ligand binds to the ligand-binding domain a conformational alteration takes place that 
promotes receptor dimerization. The dimerization of the receptors leads to 
autophosphorylation of specific residues in the intracellular tyrosine kinase domain 
(Ciardiello and Tortora, 2008; Herbst et al., 2008; Pao and Chmielecki, 2010), which 
promotes the activation of two cell signaling cascades: RAS-RAF-MEK-MAPK, which 
involved in cell growth, proliferation, cell cycle progression and controls of gene 
transcription; and PI3K-AKT-mTOR, which is involved in cell proliferation, growth, survival 
and mobility (Morgensztern and McLeod, 2005; Ciardiello and Tortora, 2008). Since 
EGFR has the capacity to form dimers, it can have two distinct natures, particularly a 
homodimer, if dimerization is established between two EGFR receptors, or a heterodimer, 
if EGFR joins to another family member like ERBB2/HER2, ERBB3/HER3 or 
ERBB4/HER4 (Ciardiello and Tortora, 2008; Sanders and Albitar, 2010). 
When an alteration occurs, the normal activity of the receptor may become 
deregulated and no longer be under control of inhibitory mechanisms, resulting in 
neoplasic mechanisms like uncontrolled cell proliferation, invasion and metastatic capacity 
or tumor-induced neoangiogenesis (Ciardiello and Tortora, 2008). This neoplasic behavior 
may be induced by amplification or overexpression of the receptor, promoting a 
Figure 5 - Members of the ERBB/HER super-
family of cell-surface receptor tyrosine 
kinase. Discrimination of all four members and 
their receptor specific ligands. The structural 
differences of the receptors are perceptible in: 
EGFR (ERBB1/HER1), ERBB3/HER3 and 
ERBB4/HER4, each presenting a ligand-binding 
domain where the receptor-specific ligands can 
bind; and EGFR (ERBB1/HER1), ERBB2/HER2 
and ERBB4/HER4, each presenting a tyrosine 
kinase domain [adapted from: Ciardiello and 
Tortora, 2008].  
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continuous activation of the EGFR receptor that leads to uncontrolled activation of 
downstream pathways. It should be noted that this sort of activation is dependent of the 
connection between specific ligands and their ligand-binding domains. Approximately 30-
59% of NSCLC have amplifications and 40-80% have overexpression of EGFR (Rusch et 
al, 1993; Hirsch et al., 2006; Herbst et al., 2008; Laurent-Puig et al., 2009). Both EGFR 
amplification and overexpression are associated with poor prognosis (Nicholson et al., 
2001). Besides this abnormal expression, mutations in EGFR gene also have the capacity 
to promote a continuous activation of downstream signaling cascade. 
EGFR somatic mutations are associated with constitutive activation of downstream 
signaling pathways of the EGFR receptor in the absence of the ligand (Sharma et al., 
2007). About 26% of NSCLC patients, average between Caucasians and Asians, carry a 
somatic mutation in EGFR gene, making this alteration one of the most frequent (Bamford 
et al., 2004; Sharma et al., 2007; Laurent-Puig et al., 2009; Bronte et al., 2010). However, 
EGFR mutational frequency varies according to some specific clinical pathological 
features, like ethnicity, gender, cancer histology and smoking status. According to the 
literature, some specific population subgroups are characterized by a higher mutational 
frequency in the EGFR gene when compared with the remaining population, being 
preferentially mutated in Asians (32%), women (38%), adenocarcinomas (30%), and non-
smokers (47%) [Figure 6] (Mitsudomi and Yatabe, 2007). Nevertheless, although with a 
lower frequencies, mutations are also found in smokers (5-15%), men (8%), squamous 
cell and large cell carcinoma (5-11%) (Chantranuwat et al., 2005; Sugio et al., 2006; 
Rosell et al., 2009).  
 
 
  
 
 
 
 
 
 
 
Figure 6 – Incidence of EGFR gene mutations according to different clinical pathological 
features. Several clinical pathological features like ethnicity, gender, smoking status and tumor 
histology play an important role in the distribution of EGFR mutations. According to the data 
Asians, women, never-smokers and adenocarcinomas represent the population group with the 
highest incidence of EGFR mutations (Hx: History) [adapted from: Mitsudomi and Yatabe, 2007]. 
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The mutational pattern of EGFR involves four exons of this tyrosine kinase 
encoding gene (Pao and Chmielecki, 2010). In NSCLC these hotspots are located in 
exons 18-21. Depending on the mutated exon, different structures around the ATP-
binding cleft of EGFR are targeted, such as the phosphate-binding loop (P-loop), the α-C-
helix, and the activation-loop (A-loop) (Kim et al., 2004). 
Activating EGFR mutations are usually classified in three major classes, although   
class I and II include the majority of mutations (85-90%) related to target therapy 
sensitivity (Greulich et al., 2005; Riely et al., 2006; Sharma et al., 2007; Kancha et al., 
2009; Bronte et al., 2010). A specific group of NSCLC patients who have sensitive-
mutations in the EGFR gene respond remarkably to tyrosine kinase inhibitors (TKI), 
something that indicates the essential role played by EGFR in NSCLC carcinogenesis 
(Lynch et al., 2004). These activating mutations can be divided in three classes. Class I 
mutations are exon 19 in-frame deletions of four amino acids downstream the lysine 
residue at position 746 (codons 747 to 750), which are denominated by LREA and 
account for 45-50% of all EGFR mutations [Figure 7] (Eberhard et al., 2005; Shigematsu 
and Gazdar, 2006; Mitsudomi and Yatabe, 2007; Gazdar, 2009). Class II mutations are 
single-nucleotide substitutions in exon 21 resulting in an amino acid substitution. The most 
common class II mutation in NSCLC is the substitution of a Leucine (Leu) to an Arginine 
(Arg) at codon 858 (p.Leu858Arg) in exon 21, which appears in 40-45% of NSCLC EGFR-
mutated cases. Other class II mutations are substitution of a Glycine (Gly) for a Serine 
(Ser), Alanine (Ala) or Cysteine (Cys) at codon 719 in exon 18 (4%), and other missense 
mutations such as substitution of a Leucine (Leu) to a Glutamine (Gln) at codon 861 
(p.Leu861Gln) in exon 21 [Figure 7] (Lynch et al., 2004; Gazdar, 2009). Class III 
mutations are characterized by in-frame duplications and insertions in exon 20 accounting 
for 5% of the activating mutations in EGFR, as well as by p.Val765Ala and p.Thr783Ala 
exon 20 point-mutations (<1%) (Sharma et al., 2007; Gazdar, 2009). 
Unlike TKI sensitizing mutations, some alterations are associated with drug 
resistance, so when detected the tumor will not respond to TKI therapy. Just about 50% of 
TKI non-responsive NSCLC acquire an amino acid substitution of a Threonine (Thr) for a 
Methionine (Met) at codon 790 (p.Thr790Met) in exon 20 [Figure 7] (Kobayashi et al., 
2005). Insertions in exon 20 like p.Asp770_Asn771insAsnProGly and 
p.Asp770_Asn771insSerValGln can also contribute to the non-response to the treatment, 
but these mutations are relatively rare (Greulich et al., 2005; Sharma et al., 2007; Gazdar, 
2010). 
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1.4.3.3 KRAS Mutations 
The RAS gene family is a superfamily of low molecular weight GTP binding 
proteins with approximately 21 kDa. In humans, the RAS family encodes three distinct but 
highly homologous proteins (HRAS, NRAS and KRAS), which play a crucial role in 
controlling the activity of several and very important signaling pathways linked to cellular 
proliferation, differentiation and apoptosis (Bos, 1989; Vojtek and Der, 1998; Pylayeva-
Gupta et al., 2011). Unlike the EGFR gene, which encodes a transmembrane receptor, 
the RAS gene family encodes transducers that couple cell surface receptors to 
intracellular effector pathways (Pylayeva-Gupta et al., 2011). 
In normal cells, the activating mechanism of RAS genes is regulated by cycling 
between inactive GDP-bound and active GTP-bound forms, also called as “off” and “on” 
conformations. Conformational alterations between GDP and GTP forms is regulated by 
guanine nucleotide exchange factors (GEFs), which stimulates a nucleotide exchange,  
and by intrinsic GTPase activating proteins (GAPs) that accelerate GTP hydrolysis (Takai 
et al., 2001; Pylayeva-Gupta et al., 2011). When activated, the GTP-binding protein 
transmits extracellular stimuli from the EGFR receptor through pathways that regulate vital 
cellular functions [Figure 8] (Downward, 1998; Vojtek and Der, 1998).  
 
 
 
 
 
 
 
Figure 7 - EGFR mutational status and comparison of TKI-sensitizing and TKI-resistant 
mutations. Mutations in exon 19 and 21 are the most frequent TKI-sensitizing mutations that 
occur in the EGFR gene, followed by exon 20 and 18 mutations. On the other hand, an exon 20 
amino acid substitution is the most frequent resistant mutation that take place in NSCLC 
(Tyrosine – Tyr) [adapted from: Pao and Chmielecki, 2010].  
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Figure 8 - EGFR receptor associated with cellular survival and proliferation pathways. 
Activation of EGFR TKI domain by a ligand biding triggers two major pathways that are related to 
cellular survival and proliferation. While the PI3K/AKT pathway control the apoptosis regulators, the 
RAS/RAF/MAPK pathway is responsible for the induction of the transcription factors in the cell 
nucleus. This last pathway is highly regulated by cycling between GDP “off” and GTP “on” 
conformation as well as by the ratio established between these two conformations [adapted from: 
Bronte et al., 2010].   
 
Similar to what happens in the EGFR gene, aberrant signaling through the RAS 
pathway can occur as a result of several mutational damage in tumor cells. Just about 
20% of human tumors have activating mutations in RAS genes, most frequently in KRAS 
(85%), followed by NRAS (15%) and HRAS (1%) (Bos, 1989). In NSCLC, KRAS point 
mutations represent 20-40% of all genetic alterations that take place in this type of lung 
cancer (Camps et al. 2010; Okudela et al., 2010;Sanders and Albitar, 2010; van Eijk et al., 
2010). Specifically, 80-90% of these point mutations happen at position 34 and 35 in 
codon 12, 10% at position 37 and 38 in codon 13, both in exon 2, and 5% in codon 61 of 
exon 3 (Keohavong et al., 1996; Krypuy et al., 2006; Sakuma et al., 2007). The most 
common mutations in codon 12 are a G>T transversion in position 34 resulting in a Gly to 
Cys substitution, and a G>T transversion in position 35 resulting in a Gly to Valine (Val) 
substitution. The rarest mutations in codon 12 are a 35G>A transversion resulting in a Gly 
to Asp and a 35G>C transversion resulting in a Gly to Ala. In codon 13 the most common 
mutations are a G>T transversion in position 37 and a G>A transversion in position 38 
resulting in a Gly to Cys and Gly to Asp substitution (Krypuy et al., 2006; Camps et al., 
2010; Zinsky et al., 2010). Transition mutations like G>A are more related with non-
smokers and G>T or G>C are more common in former/current smokers (Pham et al., 
2006; Riely et al., 2009).  
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There is an association between KRAS mutations and clinicopathological features, 
as Caucasians and former/current smokers have a higher probability of developing a lung 
adenocarcinoma with this mutations (Riely et al., 2008; Riely et al., 2009). Functionally, 
KRAS mutations compromise the GTPase activity preventing GAPs from promoting 
hydrolysis of GTP, leading to accumulation of the GTP active form and the constitutive 
activation of the signaling pathway (Bos, 1989). The major effect of the constitutive 
activation is the unresponsiveness to EGFR TKI and a poor prognosis (Eberhard et al., 
2005; Mascaux et al., 2005; Pao et al., 2005). Induction of cellular growth and apoptosis 
deregulation, metastization capacity, formation of new blood vessels and mutual 
exclusiveness with EGFR mutations are other characteristics that classify NSCLC with 
KRAS mutations (Kitamura et al., 2000; Shields et al., 2000; Riely et al., 2009).  
 
1.4.3.4 ALK Rearrangements 
The Anaplastic Lymphoma Kinase (ALK) gene belongs to the insulin growth factor 
receptor superfamily and encodes a tyrosine kinase protein with approximately 210 kDa 
(Barreca et al., 2011). Similar to the EGFR receptor, the ALK receptor also displays a 
classical structure feature of a tyrosine kinase receptor with an extracellular ligand-binding 
domain with a N-terminal signal peptide sequence, a transmembrane-spanning region and 
an intracellular tyrosine kinase domain [Figure 9] (Palmer et al., 2009). The extracellular 
domain is characterized by an unique combination of domains that contain an N-terminal 
signal peptide, two MAM domains, an LDLa motif and a glycine-rich region proximal to the 
cellular membrane [Figure 9] (Iwahara et al., 1997). Functionally, the MAM domains are 
thought to participate in cell-cell interaction, whereas the LDLa domain has an unknown 
function (Beckmann and Bork, 1993; Daly et al., 1995; Fass et al., 1997).   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9 – Human ALK receptor structure. Observation of the 
classical structure of a tyrosine kinase receptor with an 
extracellular ligand-binding domain, a transmembrane region and a 
intracellular domain. In this particullar receptor, the extracellular 
domain contains the N-terminal region that comprises two MAM 
domains, one LDLa domain and a glycine rich region. The 
intracellular region of the receptor has the protein tyrosine kinase 
domain [adapted from: Palmer et al., 2009]. 
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Little is known about the physiologic role played by this gene in mammals, but it 
may be involved in neuronal differentiation, as suggested by the ability to induce neurite 
outgrowth and the role played in synapse formation (Souttou et al., 2001; Liao et al., 2004; 
Bazigou et al., 2007; Reiner et al., 2008). High levels of expression are detected in the 
nervous system during embryogenesis, however after birth the expression of ALK 
transcript and protein diminishes, reaching a minimum level. In the adult brain, minimum 
levels of expression are maintained and it is restricted to a small region of this organ. 
Outside the nervous system, its expression is negligible (Iwahara et al., 1997).  
Normally, the receptor is found in its inactive form, which results from the absence 
of engaging ligands, promoting cellular apoptosis. Nevertheless, several mechanisms, 
such as translocations or structural rearrangements, gene amplification, mutations and 
overexpression, can promote the receptor activation and lead to a decline in the apoptosis 
rate (Mourali et al., 2006; Mosse et al., 2009). The inactive form of the ALK receptor 
facilitates apoptosis by means of its own cleavage by caspases at the D1160 residue, 
allowing the exposure of a proapoptotic intracellular domain located between residues 
1058 and 1160 (Mourali et al., 2006). It is suggested that ALK could play a role in 
programmed cell death in the chicken embryo, since the expression of the ALK transcript 
in spinal motoneurons overlaps temporally with the period of this phenomenon (Hurley et 
al., 2006; Mourali et al., 2006). When ALK is rearranged, its proapoptotic effect due to its 
cleavage by caspases is counteracted by the proliferative and prosurvival effect of the 
constitutively activated tyrosine kinase (Mourali et al., 2006). 
Of all aberrant ALK gene transformations, translocations are the most common 
cause of genomic alterations and are detected in a few number of neoplasias like 
Anaplastic Large Cell Lymphoma (ALCL), which was one of the first neoplasias where 
ALK gene translocations were described, followed by Inflamatory Myofibroblastic Tumors 
(IMTs), Neuroblastomas and, more recently, in NSCLC (Morris et al., 1994; Shiota et al., 
1994; Griffin et al., 1999; Soda et al., 2007; Chen et al., 2008). Formation of chimeric 
proteins may result from translocation or inversions and are characterized by constitutive 
ligand-independent activation of the ALK kinase domain and the consequent activation of 
downstream signaling pathways, such as RAS-MEK-ERK, JAK3-STAT3 and PI3K-AKT, 
leading to deregulation of cell survival plus cell cycling and proliferation (Chen et al., 
2008). Similarly to what happens in other neoplasias, in NSCLC ALK rearrangement 
involves several fusion partners, namely, Echinoderm Microtubule-Associated Protein-
Like 4 (EML4), TRK-Fused Gene (TFG), Kinesin Family Member 5B (KIF5B) and Kinesin 
Light Chain 1 (KLC1).  
It is noteworthy that NSCLC patients with ALK rearrangements, regardless the 
partner gene, respond to anti-ALK therapies. The presence of these fusion proteins 
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corroborates the concept that ALK has clinical relevance in the pathogenesis of lung 
cancer (Takeuchi et al., 2009; Kwak et al., 2010; Wong et al. 2011). Clinicopathological 
features like young age and adenocarcinoma histology are closely associated with ALK 
rearrangements in lung carcinomas (Tiseo et al., 2011). Features like smoking status are 
a very controversial subject ever since some studies defend smokers as the most incident 
group with ALK alterations, whereas others associate it with non/former smokers (Sasaki 
et al., 2010; Tiseo et al., 2011). Contrarily to what is observed in the mutational frequency 
of EGFR and KRAS, ALK alterations are not intimately associated with gender or with 
ethnic/racial differences (Tiseo et al., 2011). Other characteristics associated with ALK 
gene rearrangements are the mutual exclusion with EGFR and KRAS gene mutations, the 
incapacity to respond to EGFR-TKIs plus the inhibition of tumor growth and induction of 
apoptosis when targeted with small molecules anti-ALK (Soda et al., 2007; Shaw et al., 
2009; Tiseo et al., 2011). 
 
1.4.3.4.1 EML4-ALK Gene Rearrangement 
The EML4 gene is one of the five members that compose a vast family of 
Echinoderm Microtubule-Associated protein-like protein (EMLs) (Houtman et al., 2007). It 
encodes a 120 kDa protein that contains a hydrophobic Echinoderm Microtubule-
Associated Protein (EMAP) like domain unique to this family (Hamill et al., 1998; 
Heidebrencht et al., 2000). Functionally, it is a developmentally regulated protein, since its 
expression is mainly detected in developing embryos, but also persists in the adult 
olfactory bulb, hippocampus and cerebellum in a lower level. It is also associated with and 
stabilizes microtubules (Houtman et al., 2007). 
The EML4-ALK fusion gene results from a small inversion within the short arm of 
chromosome 2, inv(2)(p21p23), leading to the expression of a chimeric tyrosine kinase 
with a potent oncogenic activity. The fusion protein contains the N-terminal half of EML4 
protein joined to the tyrosine kinase domain of ALK [Figure 10] (Soda et al., 2007; Chiarle 
et al., 2008). Only 1-6% of all NSCLC have been identified with this alteration (Tiseo et al., 
2011). 
 
 
 
 
Figure 10 – Structure of the EML4-ALK fusion gene. The fusion gene is composed by the 
coiled-coil domain of the EML4 gene and the tyrosine kinase domain of ALK gene. The presence of 
this specific region of EML4 promotes the constitutive activation of ALK tyrosine kinase, leading to 
cellular behavior deregulation [adapted from: Sasaki et al., 2010]. 
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Until very recently, 15 variants of EML4-ALK fusion protein have been described 
involving eight different EML4 exons, specifically exons 2, 6, 13, 14, 15, 17, 18 and 20, 
and exon 20 of ALK (Sanders et al., 2011). The difference between the variants relies on 
the fact that the chromosomal inversion does not always take place in the same location. 
In other words, while the ALK portion of the chimeric protein is always the same, the 
EML4 is variably truncated, giving rise to the numerous variants of EML4-ALK [Table 1]. 
Approximately 33 and 29% of all variants detected are variants 1 and 3a/b, respectively, 
making these the most frequent EML4-ALK variants in NSCLC patients [Table 1]. 
Although each variant present different structural features, the clinical significance of each 
one of them is currently not defined. However, the high number of variants makes 
molecular diagnostic testing more challenging (Sasaki et al., 2010; Ou, 2011; Sanders et 
al., 2011). 
 
 
Table 1 - Name, EML4 exon and frequency of the 15 variants of EML4-ALK [adapted from: 
Sasaki et al., 2010; Sanders et al., 2011]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.4.3.4.2 TFG-ALK Gene Rearrangement  
TRK-Fused Gene (TFG) has been mapped in the long arm of chromosome 3, 
3q11.12, and has the capacity to trigger tyrosine kinase genes in a constitutive way, due 
to oncogenic alterations. The genomic rearrangement TFG-ALK is composed by the 5’ 
region of TFG, including the coiled-coil oligomerization domain of the protein, and the 3’ 
EML4-ALK 
Variant 
EML4 Involvement 
(exon) 
Variant 
Frequency (%) 
1 13 33 
2 20 9 
3a, 3b 6 29 
4 14 2 
5a, 5b 2 2 
6 17 3 
7 20/14 3 
8a, 8b 17 4 
V4 15 3 
V5 18 2 
E17;ins68A20  1 
E20;ins18A20  9 
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region of ALK responsible for tyrosine kinase domain codification [Figure 11] (Hernández 
et al., 1999; Rikova et al., 2007). This rearrangement was found in only one NSCLC case 
(Rikova et al., 2007). 
 
 
 
 
Figure 11 - Structure of the TFG-ALK fusion gene. The fusion gene is composed by a coiled-coil 
domain codified by the TFG gene, and a tyrosine kinase domain codified by ALK gene. It is the 
presence of this coiled-coil domain that will constitutively activate the tyrosine kinase domain of the 
fusion protein [adapted from: Sasaki et al., 2010]. 
 
1.4.3.4.3 KIF5B-ALK Gene Rearrangement 
Kinesin Family Member 5B (KIF5B) gene is located on the short arm of 
chromosome 10, 10p11.22, and encodes a member of the superfamily of microtubule-
associated ATPases (Hirokawa, 1998; Goldstein and Philip, 1999). It is a component of a 
motor protein complex, associated with microtubules, which transforms energy from ATP, 
so cellular mechanisms like mitosis, meiosis and transport of organelles can be performed 
(Vale and Fletterick, 1997). The protein is composed by an amino terminal motor domain 
followed by a neck domain and a stalk region that mediates directly homodimerization of 
KIF5B (Sablin, 2000; Takeuchi et al., 2009). Formation of KIF5B-ALK fusion protein, 
results from the fusion of exons 1 to 24 of the KIF5B gene, which codifies the motor, neck 
and stalk domains, to ALK tyrosine kinase domain, encoded by exon 20 [Figure 11]. 
Similar to what happens in other ALK rearrangements, in KIF5B-ALK the constitutive 
activation of the tyrosine kinase domain is promoted by the coiled-coil domain of the 
fusion partner, which in this case is the homodimerization mediated by the stalk region of 
KIF5B [Figure 11]. These alterations were reported in 0.5% of lung adenocarcinomas and 
exhibit an eosinophilic cytoplasm and a large vesicular nucleus with one or two prominent 
nucleoli (Takeuchi et al., 2009). 
It would be expected that the same signaling pathways are affected by this 
rearrangement, since the presence of the tyrosine kinase domain of ALK gene is present 
in both EML4-ALK and KIF5B-ALK. However, signals downstream of KIF5B-ALK differs 
from that of other ALK rearrangements because of the differential phosphorylation of 
STAT proteins associated with this fusion protein (Amstrong et al., 2004). More recently, it 
was described a novel variant characterized by the fusion between ALK with exon 15 of 
KIF5B. Despite the difference, the KIF5B coiled-coil domain and ALK tyrosine kinase 
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domain are the same in both variants. The sample which expresses this variant is a poorly 
differentiated adenocarcinoma of mixed subtype (Wong et al., 2011). 
 
 
 
 
 
Figure 12 - Structure of the KIF5B-ALK fusion gene. The KIF5B gene is composed by an amino 
terminal motor domain followed by a neck domain and a stalk region, also known as coiled-coil 
domain, which promotes the homodimerization of ALK tyrosine kinase domain. Analogous to the 
EML4-ALK rearrangement, in this case the ALK gene also retains the tyrosine kinase domain 
[adapted from: Sasaki et al., 2010].   
 
1.4.3.4.4 KLC1-ALK Gene Rearrangement 
Kinesin Light Chain 1 (KLC1) is the most recent discovered ALK fusion partner 
(Togashi et al., 2012). Its main function is played by the binding of the N-terminal domain 
of the protein to the kinesin heavy chains, as well as to various cargos via tetratricopepite 
repeat domains. Whereas EML4 is colocalized with microtubules and may contribute to 
their stabilization and KIF5B moves on the microtubules as a kinesin heavy chain, KLC1 
binds to kinesin heavy chains as a kinesin light chain and may play different roles in 
intracellular transport in neuronal cells (Stenoien and Brady, 1997; Rahman et al., 1999; 
Sablin, 2000; Houtman et al., 2007). Therefore, it can be concluded that all four ALK 
fusion partners, in NSCLC, are colocalized with microtubules. Similar to TFG, KLC1 is 
also an uncommon ALK fusion partner in NSCLC, being only reported in one case. The 
reported case belongs to a NSCLC patient with a nonmucinous adenocarcinoma in situ 
(Togashi et al., 2012). 
 
1.5 Lung Cancer Treatment 
Lung cancer treatment depends on the histological type, stage and the mutational 
status of the tumor and often a combination of several therapeutic mechanisms is 
necessary. The most common therapeutic approaches for NSCLC are surgery, 
radiotherapy, chemotherapy and target therapy. 
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1.5.1 Surgery 
Oncologic surgery is based on the capacity to remove all the tumoral mass. It is 
the most consistent and successful option to cure lung cancer patients, when complete 
resection is achieved (Molina et al., 2008). Before intervention, a team of thoracic 
surgeons determines the resection grade of the tumor and, according to their 
classification, the tumor is removed or not (National Comprehensive Cancer Network, 
2012). 
When a wide pulmonary resection is needed in resectable tumors, the standard 
surgical management is the lobectomy. The advantages are an increase in long-term 
survival, a decrease of local recurrence and a low operative mortality of 1.3%. In order to 
be a therapeutic alternative, the patients must tolerate such intervention and the tumor 
must not show evidence of lymph node spread (Allen et al., 2006; Molina et al., 2008). 
Some of these inconveniences can be overcome with video-assisted lobectomy, since it is 
a less invasive method for achieving total tumoral resection, with a similar long-term 
survival, and patients that were not candidates for standard pulmonary surgery, because 
of its morbidity, can be operated. On the other hand, small, peripheral bronchoalveolar or 
other low-grade lung tumor can be adequately treated with a segmentectomy or wedge 
resection (Molina et al., 2008). It is noteworthy to remember that these surgeries are only 
applied in tumors with stage I, II and possibly III (National Cancer Institute, 2011). 
Besides its therapeutic value, surgery can also be used as a way for diagnosis, 
staging and palliative care (Molina et al., 2008). 
 
1.5.2 Radiotherapy 
 Radiotherapy (RT) is useful for treatment of unresectable lung cancer, whether it 
is an early or advance tumor, using high-energy rays (National Cancer Institute, 2007; 
Molina et al., 2008). Such potential role allows radiotherapy to be classified as a definitive 
or palliative therapy (National Comprehensive Cancer Network, 2012). When 
implemented as a single therapy, the median survival is ten months and the 5-year SR is 
5%. When combined with cisplatin/paclitaxel-based chemotherapy produces better 
survival rates in a small number of patients and can provide palliation in most cases 
(Molina et al., 2008; National Cancer Institute, 2011; National Comprehensive Cancer 
Network, 2012). 
Radiotherapy schemes can be external, like stereotatic RT or hadron therapy, or 
internal, like brachytherapy (National Cancer Institute, 2007; Molina et al., 2008). 
Stereotactic RT is a technique that includes fixation, ultraprecision on treatment planning, 
guidance of RT to gross disease alone and high doses per fraction. It is mainly used for 
Introduction 
33 
 
treatment of small lung cancers with a low grade (stage I and II) and is characterized by 
an 5-year SR of 81%. On the other hand, hadron therapy is based upon the strong 
nuclear force of a subatomic particle named hadron. The main advantages when 
compared with conventional RT are higher relative biologic effectiveness, higher linear 
energy transfer, lower oxygen-enhancement ratio and great dose distribution. Its 
complexity and high cost are the two main disadvantages of this methodology (Molina et 
al., 2008). Brachytherapy is a RT method in which a seed, wire or other radioactive device 
is placed inside the patient body where it gradually releases radioactive rays that kill the 
malignant cells. This class of RT is mainly implemented in a tumoral recurrence or 
metastasis when it is verified an endobronchial obstruction or a severe hemoptysis 
(National Cancer Institute, 2007; National Comprehensive Cancer Network, 2012). 
 
1.5.3 Chemotherapy   
Chemotherapy is based on the administration of anticancer drugs with cell 
destruction capacity, regardless of their normal or neoplasic nature (National Cancer 
Institute, 2007). Comparable to what happens in RT, chemotherapy administration can 
also occur in low-grade, resected stages II and III, as well as in high-grade, locally 
advanced and metastatic disease (Pfister et al., 2004; Molina et al., 2008). Low-grade 
chemotherapy can be divided in neoadjuvant (preoperative regimens) or adjuvant 
(postoperative regimens). Neoadjuvant regimens benefits are reduction in tumor size that 
may facilitate surgical resection, early eradication of micrometastases and better 
tolerability, but it may delay potentially curative surgery. When administrated, it provides 
an absolute benefit in survival of 6% across stages I, II and III of disease from 14 to 20% 
at 5-years (National Cancer Institute, 2011). Adjuvant regimen is implemented since a 
high risk of relapse is associated with resected lung cancers. They are based in cisplatin-
based chemotherapy combined with vinorelbine, which provides a significant survival 
benefit of 15% at 5-years and a 30% relative reduction in the death risk (DR) (Molina et 
al., 2008; National Cancer Institute, 2011).   
Metastatic lung cancer patients are treated with the intention to prolong survival 
and to control disease-related symptoms. Treatment options include platinum-based 
chemotherapy combined with several agents, like paclitaxel, docetaxel, gemcitabine, 
vinorelbine, irinotecan and pemetrexed, as well as combination with target therapy drugs 
like bevacizumab or cetuximab (National Cancer Institute, 2011; National Comprehensive 
Cancer Network, 2012). Platinum-based chemotherapy prolongs survival, improves 
symptom control, yields superior quality of life and reduces death risk. Statistically 
speaking, it is responsible for an overall response rate (ORR) of 25-30%, a time 
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progression of 4-6 months, median survival of 8-10 months, 1-year SR of 30-40% and 2-
year SR of 10-15%. Death and survival rates nevertheless vary depending on the 
chemotherapy regimens, combinations and clinicopathological features like NSCLC 
histology, age and performance status (Molina et al., 2008; National Cancer Institute, 
2011; National Comprehensive Cancer Network, 2012). 
 
1.5.4 Target Therapy  
Target therapy is applied in cancer treatment in order to block cancer cells growth 
by interfering with specific molecules that are needed for tumor development and growth. 
Contrary to what happens in chemotherapy drugs, which simply interfere with rapidly 
diving cells whether they are normal or tumoral, target therapy drugs are more effective, 
less harmful to normal cells and present better-tolerated side effects. Regarding to drug 
structure, target therapy drugs can be classified in two main categories: Monoclonal 
Antibodies (MoAb) and small-molecule inhibitors, also called tyrosine kinase inhibitors 
(TKI). Monoclonal antibodies bind to the extracellular domain of a transmembrane 
receptor, in its inactive configuration, by competing with the receptor-ligand for the 
receptor binding domain (and sometimes hampering receptor dimerization). Once MoAb 
links to the receptor binding domain, blocking of ligand-induced tyrosine kinase takes 
place promoting an inactivation of all signaling pathways downstream of receptor 
(Ciardiello and Tortora, 2008). Small-molecule inhibitors compete reversibly with ATP 
molecule to bind to the tyrosine kinase domain of the receptor, resulting in the inhibition of 
receptor autophosphorilation and downstream signaling (Ciardiello and Tortora, 2008). 
 
1.5.4.1 Monoclonal Antibodies (MoAb) 
Combination between chemotherapy plus bevacizumab or cetuximab is indicated 
as first-line therapy in patients with a performance status of 0-1, according to Zubrod 
score, with advanced or recurrent NSCLC (National Comprehensive Cancer Network, 
2012). 
 
1.5.4.1.1 Bevacizumab 
Bevacizumab is a humanized monoclonal antibody that binds and neutralizes the 
Vascular Endothelial Growth Factor-A isoform (VEGF-A), preventing VEGF ligand-
receptor binding and inhibiting the VEGF/VEGF receptor signaling pathway (Planchard, 
2011). Its main mechanism of action is blockage of new vessels, inducing a more normal 
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vasculature pattern and reducing interstitial fluid pressure and vascular permeability. 
These alterations are intended to restore normal function to blood vessels, so delivery of 
chemotherapeutic agents and oxygen to tumor cells is easier (Jain, 2005). When 
associated with first-line chemotherapy for advanced-stage NSCLC, the median and 1-
year SR is 12.9 months and 49%, respectively, and a progression-free survival (PFS) of 
6.7 months (Planchard, 2011). Consistent benefits are demonstrated when bevacizumab 
is used in combination with first-line chemotherapy regimens, such as a tolerable and 
safety profile to patients subgroups with central nervous system metastases, receiving 
anticoagulation therapies and elderly (Planchard, 2011). 
 
1.5.4.1.2 Cetuximab 
Cetuximab is a human-murine chimeric IgG1 monoclonal antibody acting as a 
competitive antagonist of the natural ligand, which binds to the extracellular domain of 
EGFR receptor and promotes a blockage of ligand-induced EGFR tyrosine kinase 
activation (Baselga et al., 2000). First-line chemotherapy regimens/cetuximab combination 
is still at clinical trials as a manner to understand and characterize its benefits as a 
therapy to administrate in high-grade NSCLC, and its side effects to specific NSCLC 
patients groups. The most recent clinical trials (FLEX and BMS099) demonstrate a benefit 
in overall survival (OS) of approximately 1 month, but not in PFS, as well as a reduction in 
DR of 13%. A relevant survival benefit was verified in advanced NSCLC that express high 
levels of EGFR by immunohistochemistry (IHC), when cetuximab is added to first-line 
chemotherapy. These findings may contribute to the identification of a predictive marker 
for cetuximab activity in NSCLC. Besides these outcomes, results of ongoing clinical trials 
will define the role of cetuximab combined with chemotherapy as first line therapy in 
advanced disease (Carilio et al., 2012). 
 
1.5.4.2 Tyrosine Kinase Inhibitors (TKI) 
1.5.4.2.1 Gefitinib 
Gefitinib is an oral small-molecule inhibitor that specifically inhibits the tyrosine 
kinase domain of the EGFR receptor and is clinically available in the treatment of NSCLC 
(Mitsudomi, 2010). Its main mechanism of action is targeting the ATP binding region of the 
tyrosine kinase domain, promoting a blockage in signal transduction pathways implicated 
in proliferation, survival and growth of cancer cells (Wakeling et al., 2002; Nakagawa et 
al., 2003). When tested, it was found that it inhibited EGFR tyrosine kinase activity at low 
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concentrations and when administrated as a single agent it potentiated the activity of 
cytotoxic agents (Ciardiello et al., 2000; Woodburn et al., 2000). 
Various studies were conducted to compare the benefits of gefitinib with 
chemotherapy. In 2009, two phase III studies demonstrated that EGFR TKI, as an initial 
treatment, is superior to chemotherapy in lung cancer with mutations in EGFR (Mok et al., 
2009; Mitsudomi, 2010). Other study compared East Asians, never/former smokers, with 
lung adenocarcinoma positive or negative for EGFR mutations and it was verified that 
PFS was significantly longer among patients who received gefitinib and present mutations 
in the EGFR gene. Patients with wild-type EGFR have a PFS significantly longer when 
treated with chemotherapy regimens (Mok et al., 2009). Regarding the benefit of gefitinib 
or chemotherapy as first-line therapy in NSCLC positive for EGFR showed an OS of 30.5 
months versus 23.6 months, respectively, as well as a higher symptomatic improvement, 
a better quality of life and more favorable toxicity profile for gefitinib. When applied in 
second-line therapy, response rate (RR) of these TKI decreased from 73.7% to 58.5%, 
which corroborates the advantage of keeping gefitinib as a first-line therapy (Maemondo 
et al., 2010; Gridelli et al., 2011). Throughout the studies it became obvious that specific 
population groups, like Asians, non/former smokers, women and adenocarcinomas, have 
better responses to gefitinib than the remaining. With a closer look, it became clear that 
this subgroup is the same that shows a high frequency of mutations in the EGFR gene 
(Lynch et al., 2004; Paez et al., 2004; Pao et al., 2004). 
According to what has been described in several studies, NSCLC patients who 
have mutations in EGFR gene respond remarkably to gefitinib, which indicates the 
essential role played by EGFR in NSCLC carcinogenesis (Lynch et al., 2004). Not all 
mutations that occur in EGFR confer a positive response to TKI. The so-called somatic 
sensitizing mutations occur at the ATP-binding pocket in the tyrosine kinase domain of the 
receptor, which is also the binding site of gefitinib. The presence of these mutations 
results in preferential binding of gefinitib instead of ATP molecules at the ATP-binding 
pocket, resulting in cell death mediated through the intrinsic apoptotic pathway (Pao and 
Chmielecki, 2010). The main sensitizing mutations in EGFR gene occur in exons 19 and 
21, and NSCLC harboring exon 19 deletions seem to respond better to gefitinib than 
tumors with point mutations in exon 21 (Mitsudomi et al., 2005; Sharma et al., 2007). 
Several studies report that 50-80% of NSCLC with EGFR-sensitizing mutations respond to 
TKI treatment, but the duration is only of about 6-12 months before resistant disease 
recurs (Inoue et al., 2006; Niho et al., 2006; Suzuki et al., 2006; Sharma et al., 2007). 
Besides TKI-sensitizing mutations, alterations conferring resistance to the 
treatment may also take place in NSCLC. The most frequent TKI-resistant mutation is 
p.Thr790Met in exon 20, which is responsible for acquired resistance to gefitinib, because 
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it alters the topology of the ATP-binding pocket increasing the affinity of the tyrosine 
kinase domain for ATP (Kobayashi et al., 2005; Kumar et al., 2008; Yun et al., 2008). 
However, some studies have also shown that p.Thr790Met may also be classified as a 
primary resistance mutation, since they may be present before the patient is exposed to 
treatment (Kosaka et al., 2004; Bell et al., 2005; Gow et al., 2005; Shih et al., 2005; Kwak 
et al., 2006). The presence of low levels of p.Thr790Met in pretreated NSCLC cells 
confers the ability to proliferate even in presence of gefitinib. In the end of the treatment, 
the surviving NSCLC cells are preferentially those which harbored TKI-resistant mutations 
(Inukai et al., 2006; Sharma et al., 2007; Gazdar, 2009). 
Besides the p.Thr790Met mutations in pretreated NSCLC, other mechanisms of 
primary resistance are insertion mutations in exon 20 of the EGFR gene, mutations in the 
KRAS gene and ALK fusion proteins. Although insertions in exon 20 of EGFR are very 
rare, it was suggested that when present it might render the receptor about 100-fold less 
sensitive to gefitinib compared with TKI-sensitive mutations. The difference between exon 
20 insertions and TKI-sensitizing mutations may reside in their downstream signals or the 
differential binding affinity to ATP and the inhibitors (Greulich et al., 2005; Sharma et al., 
2007; Wu et al., 2008). KRAS gene mutations occur mainly in codons 12 and 13 of exon 
2. Normally these mutations are found in EGFR wild-type tumors, so it is difficult to 
unequivocally determine whether insensitivity is due to mutations in the KRAS gene or the 
absence of mutations in EGFR (Pao et al., 2005; Sharma et al., 2007; Pao and 
Chmielecki, 2010). Fusion proteins evolving ALK gene are found in a small percentage of 
NSCLC, being EML4-ALK the most frequent rearrangement. Positive tumors for ALK 
rearrangements are incapable of responding to EGFR TKI treatment (Soda et al., 2007; 
Shaw et al., 2009).   
MET proto-oncogene amplification takes place in 20% of lung cancers and confers 
a TKI failure. Amplification of the MET proto-oncogene undergoes a kinase switch on MET 
signaling pathway, promoting activation of the EKT pathway independently of the 
presence of EGFR TKI. Normally MET amplification is classified as a mechanism of 
acquired resistance, but one case has already been described with amplification of MET 
before treatment administration, making it also a mechanism of primary resistance similar 
to what was described for the p.Thr790Met mutations. Similarly to what happens in 
primary resistance associated with some EGFR mutations, it has been suggested that TKI 
therapy may select pre-existing cells with MET amplification (Bean et al., 2007; Engelman 
et al., 2007; Pao and Chmielecki, 2010). 
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1.5.4.2.2 Erlotinib 
Erlotinib is the name of a second EGFR TKI that shows similar functional 
characteristics with gefitinib. It is also a small-molecule with a specific configuration to 
bind to the ATP pocket of the EGFR receptor tyrosine kinase domain and block several 
intracellular signaling pathways (Moyer et al., 1997; Pollack et al., 1999). The applicability 
of this drug in NSCLC treatment is confined to all subgroups of advanced NSCLC after 
failure of at least one prior chemotherapy regimen, presence of activating mutations in 
EGFR, as third-line treatment after second-line chemotherapy failure and whose disease 
is stable after receiving four cycles of standard chemotherapy (Vincent, 2009; Reguart et 
al., 2010). 
The presence of activating mutations, either in-frame deletion in exon 19 or point 
mutations in exon 21 (p.Leu858Arg) are intimately associated with tumor response to 
erlotinib. (Pao et al., 2004; Mitsudomi et al., 2006). On the other hand, exon 20 point 
mutations (p.Thr790Met), amplification of MET proto-oncogene, mutations in KRAS gene 
and rearrangements involving ALK gene are mechanisms that confer a high level of TKI 
resistance to erlotinib, similarly to what happens with gefitinib (Engelman et al., 2007; 
Engelman and Settleman, 2008; Hammerman et al., 2009). Exon 19 deletions are 
associated with a complete response of 12%, a better outcome, PFS of 14 months and an 
OS of 27 months, when compared with mutations in exon 21 (Rosell et al., 2009). 
According to the literature, erlotinib is administrated to all subgroups of locally 
advanced or metastatic NSCLC after failure of at least one prior chemotherapy regimen 
(Reguart et al., 2010). However, several trials compared first-line chemotherapy regimens 
to erlotinib in order to determine if this EGFR TKI could be considered as a new standard 
option in first-line intervention. Results demonstrate that median PFS was 4.6 months with 
chemotherapy, compared to 13.1 months with erlotinib, and objective response rate was 
also superior to chemotherapy, 83% vs 36%, respectively, with favorable toxicity profiles 
(Reguart et al., 2010). These values demonstrate that erlotinib is a good candidate to be 
implemented as first-line therapy in EGFR-mutation positive tumors. However, and since 
gefitinib is also considered as a first-line therapy in EGFR positive NSCLC, both drugs 
could be chosen as first-line treatment. Unfortunately, no study is available that compares 
gefitinib to erlotinib, although some pharmacokinetics differences are known, such as the 
standard clinical dose that is one third of its maximum tolerated dose in gefitinib, whereas 
in erlotinib is at its maximum tolerated dose. While toxicity profile of both drugs is similar, 
the difference in dose can lead to different frequency of some side effects (Reguart et al., 
2010). 
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1.5.4.2.3 Crizotinib 
Crizotinib is a multitarget receptor tyrosine kinase inhibitor that was initially 
synthesized as a MET inhibitor. As a TKI, it interacts with the ATP-binding site of the 
receptor kinase domain through direct competition with ATP molecule. A similar TKI 
behavior is observed in ALK-positive tumors, and it was determined that crizotinib was 20-
fold more selective for ALK and MET than other kinases (Ou, 2011). Clinical efficacy has 
been consistent in several studies, showing RR of 61%, an estimated PFS of 10 months, 
and more rapid symptomatic relief and tumor shrinkage. According to these results, 
crizotinib could be used for first-line treatment of patients with advanced ALK-positive 
NSCLC (Kwak et al., 2010; Ou et al., 2010; Ou, 2011; National Comprehensive Cancer 
Network, 2012).   
Being the presence of ALK rearrangements in NSCLC the main predictive factor 
for tumor response to crizotinib, mechanisms that promote resistance to the therapy have 
already been identified. These mechanisms are two acquired but independent mutations 
within the kinase domain of EML4-ALK, namely p.Cys1156Tyr and p.Leu1196Met (Choi et 
al., 2010; Doebele et al., 2012). The p.Leu1196Met mutation was already identified in 
other NSCLC patients and is characterized as the major mechanism of resistance to 
crizotinib (Pao et al., 2005; Choi et al, 2010; Katayama et al., 2011). As it might be 
expected, “second-generation” ALK TKI are being clinically tested, so that crizotinib 
resistance can be overcome, namely, AP26113, which is a hundred times more potent 
than crizotinib in inhibiting ALK with the p.Leu1196Met mutation, CH542802, which 
strongly inhibits wild-type ALK as well as that with the p.Leu1196Met mutation, and IPI-
504, which is a potent Heat Shock Protein 90 (HSP90) inhibitor (Katayama et al., 2011; 
Normant et al., 2011; Ou, 2011; Sakamoto et al., 2011; Doebele et al., 2012). The main 
difficulty of these studies is that the number of patients with resistance mechanisms to 
crizotinib is extremely small (Ou, 2011). Other resistant mechanisms that can occur have 
an intrinsic nature such mutations in either EGFR or KRAS genes in ALK-negative 
NSCLC (Katayama et al., 2011; Doebele et al., 2012). 
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2. Aims 
 
A consecutive series of DNA samples from NSCLC patients previously analyzed 
for EGFR mutations was studied. The major goals of this work were: 
 
 To evaluate two different methodologies (fragment analysis and TaqMan  SNP 
genotyping assay) for detection of the most common EGFR exon 19 and 21 
mutations, and to compare the findings with those of the currently used 
methodologies for routine EGFR testing in the IPO-Porto Genetics Department; 
 
 To characterize the frequency and pattern of KRAS exon 2 mutations; 
 
 To determine the frequency of fusion genes involving the ALK gene; 
 
 To evaluate the mutual exclusivity hypothesis of mutations involving the EGFR, 
KRAS and ALK genes in NSCLC carcinogenesis. 
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3. Materials and Methods 
 
3.1 Samples 
A consecutive series of DNA samples from 207 patients with NSCLC (194 
formalin-fixed, paraffin-embedded tissues sections and 13 cytology specimens) were 
retrospectively analyzed. These patients were referred to the IPO-Porto Genetics 
Department, between January 2010 and March 2011, for EGFR exons 18, 19, 20 and 21 
mutation analysis by HRM amplification followed by DNA sequencing. Of these 207 DNA 
samples, nine were excluded due to lack of DNA for further studies. Of the total of 198 
analyzed samples, 58 women and 140 men, clinical features were not available for seven 
cases treated in other hospitals. In total, clinical data was available for 191 cases, being 
54 women and 137 men, 45 former smokers and 49 smokers (for 97 patients no 
information was available on smoking status at the time of writing), and a mean age at 
diagnosis of 63 years (minimum age of 33 years, maximum age of 89 years). There were 
132 adenocarcinomas, 41 squamous cell carcinoma, seven large cell carcinoma, one mix 
pattern carcinoma (adenocarcinoma compound associated with a large cell carcinoma 
compound), one adenosquamous carcinoma, one mucoepidermoid carcinoma and eight 
samples with nonspecified histology.  
Of the initial series of 207 patients, 29 (nine men and 20 women) presented an 
EGFR mutation [Table 2]. Clinical features were available for 27 of the 29 cases with 
EGFR mutations (seven men and 20 women), with a mean age at diagnosis of 68.4 years 
(minimum age of 49 years, maximum age of 78 years). In total, this series consists of 23 
adenocarcinomas, two squamous cell carcinoma, one mix pattern carcinoma 
(adenocarcinoma component associated with a large cell carcinoma component), and one 
adenosquamous carcinoma. 
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EGFR Exon HGVS Protein 
HGVS DNA No. 
Samples 
19 
p.Glu746_Ala750del  c.2235_2249del 6 
p.Glu746_Ala750del  c.2236_2250del 2 
p.Glu746_Thr751delinsIle c.2236_2252delinsAT 1 
p.Glu746_Thr751delinsAla  c.2237_2251del 1 
p.Glu746_Ser752delinsVal  c.2237_2255delinsT 1 
p.Leu747_Ala750delinsPro  c.2239_2248delinsC 2 
p.Leu747_Ala750delinsPro  c.2238_2248delinsGC 1 
p.Leu747_Thr751del  c.2240_2254del 1 
p.Leu747_Ala755delinsSerLysAsp  c.2240_2265delinsCGAAAGAT 1 
p.Asp761Tyr  c.2281G>T 1 
20 p.Asn771_His773dup  c.2311_2319dup 1 
21 
 
p.Leu858Arg  c.2573T>G 9 
p.Leu861Gln  c.2582T>A 1 
19+21 p.[Gly735Ser(;)Pro848Ser] c.[2203G>A(;)2542C>T] 1 
 
3.2 DNA Extraction From Formalin-fixed, Paraffin-embedded Tissues 
Slides that were previously stained with Hematoxylin & Eosin (H&E) were reviewed 
by a pathologist, who delimited the area containing at least 70% of tumor cells. Tissue 
sections, with 10µm of thickness, were obtained from formalin-fixed, paraffin-embedded 
tissues (FFPE) and were placed on 0.1% Poli-L-lysine coated slides and dried at 37°C 
overnight. 
DNA extraction began with the slides being soaked on xylene [SIGMA] for 5 minutes 
and twice in 100% ethanol [Merck] solution, for 5 minutes each, to remove the paraffin. 
Tumor areas were carefully delimited based on the H&E stained section and scraped 
using a sterile scalpel blade. The tissue scraped was transferred to a microcentrifuge 
tube, to which 180µl of lysis buffer [QUIAGEN] and 40µl of proteinase K [QUIAGEN] were added, 
followed by incubation at 55°C overnight. In the next day, the microcentrifuge tube was 
incubated at 90°C for 1 hour, for proteinase K [QUIAGEN] inactivation, and the DNA was 
extracted using the QIAamp® DNA FFPE Tissue kit [QUIAGEN] that is used in the automatic 
DNA extractor QIAcube [QUIAGEN]. DNA quantity was evaluated using NanoDrop ND-1000
® 
[NanoDrop Tecnologies]. 
 
Table 2 – EGFR mutations identified in 29 patients with routine genetic testing. 
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3.3 DNA Extraction From Cytological Samples 
Fresh specimens were extended over a microscope slide and fixed with 96% ethyl-
alcohol and stained with hematoxylin. Cover slides were placed to observe and mark the 
presence of malignant cells, if present. Tumor cells were identified by a pathologist. 
For DNA extraction, the slides were first soaked in xylene [SIGMA] for 24-48 hours to 
remove the cover slide. When the cover slide was removed, the slide was soaked in a 
decreasing gradient of alcohols, 100%, 90% and 80%, 5 minutes each. All tissue was 
scraped using a sterile scalpel blade to a microcentrifuge tube, where 180µl of lysis buffer 
(100mL total volume: 5mL of Tris-HCL [SIGMA No T-3523] 1M(pH8.5), 1mL of EDTA [E-5134], 
500µl of Tween 20 [GIBCO BRL 900-64-5], bidestilled sterile water [B.Braun]), and 40µl of proteinase 
K [QUIAGEN] was added, followed by incubation at 55ºC overnight. In the next day, the 
microcentrifuge tube was incubated at 90ºC for 15 minutes, for proteinase K [QUIAGEN] 
inactivation, followed by a 10000rpm centrifugation for 5 minutes. The supernatant was 
transferred to a new microcentrifuge tube and the pellet was stored at -20ºC. DNA 
quantification was evaluated using NanoDrop ND-1000® [NanoDrop Tecnologies].  
 
3.4 EGFR Exons 19 and 21 Analysis 
3.4.1 Fragment Analysis 
Mutational status of EGFR exon 19 was determined through fragment analysis 
according to Rosell et al (2008). The initial PCR reaction was executed with 1.25x of Taq 
Buffer [Fermentas], 31µM of MgCl2 [Fermentas], 1.5µM of dNTP’s [Applied Biosystems], 5 U of Taq DNA 
Polymerase [Fermentas], 1.5 µM of each primer [Frilabo], 50 ng of DNA sample and distilled 
water [B Braun] to reach a total volume of 20 µl. The primers [Frilabo] were forward 5’-
GCAATATCAGCCTTAGGTGCGGCTC-3’ and reverse 5’-
CATAGAAAGTGAACATTTAGGATGTG-3’, as described by Rosell et al (2008). 
Amplification was performed in a thermocycler and the program used had an initial 
denaturation step at 95°C for 5 minutes, followed by 35 cycles of denaturation at 95°C for 
1 minute, annealing at 55°C for 1 minute, extension at 72°C for 1 minute and a final 
extension at 72°C for 10 minutes. Products were analyzed in a 2% (w/v) agarose gel 
stained with ethidium bromide. 
The nested-PCR reaction was performed with 1.25x of Taq Buffer [Fermentas], 31µM 
of MgCl2 [Fermentas], 1.5 µM of dNTP’s [Applied Biosystems], 5 U of Taq DNA Polymerase [Fermentas], 
1.5 µM of each primer and 30-90 ng of DNA in a total volume of 20 µl. The primers [Frilabo] 
were forward 5’-ACTCTGGATCCCAGAAGGTGAG-3’ and reverse 5’-FAM-
CCACACAGCAAAGCAGAAACTC-3’ (Rosell et al., 2008). The samples were amplified in 
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a thermocycler and the amplification program was an initial denaturing step at 95°C for 5 
minutes, 35 cycles with denaturation at 95°C for 1 minute, annealing at 55°C for 1 minute 
and extension at 72°C for 1 minute, a final step of extension at 72°C for 10 minutes was 
added. 
The final products were analyzed using a 2% (w/v) agarose gel stained with 5 µl of 
ethidium bromide. Samples were eluted in 15 µl of deionized formamide [Applied Biosystems] 
plus 0.5 µl of GeneScan™ - 500 ROX™ Size Standard [Applied Biosystems]. All PCR products 
were run on an ABI PRISM™ 310 Genetic Analyzer [Applied Biosystems] and analyzed by the 
GeneMaper Software Version 3.7 [Applied Biosystems]. 
  
3.4.2 TaqMan SNP Genotyping Assay 
A TaqMan assay was used to study the mutation p.Leu858Arg in EGFR exon 21 
(Rosell et al, 2008). The first amplification was performed with the following primers: 
forward 5’-GCAATATCAGCCTTAGGTGCGGCTC-3’, and reverse 5’-
CATAGAAAGTGAACATTTAGGATGTG-3’ (Rosell et al., 2008). Amplification was 
performed as described above for fragment analysis first PCR (Rosell et al., 2008). 
The products of the first PCR were amplified by 5µl AmpliTaq Gold® PCR Master 
Mix [Applied Biosystems], 0.2 µM of each primer [Frilabo], 5 pmol of each probe [Applied Biosystems], 0.16 
µl of Rox Reference Dye [Invitrogen] and 30-90 ng of DNA in a final volume of 10 µl. Primers 
[Frilabo] and probes [Applied Biosystems] were forward 5’-AACACCGCAGCATGTCAAGA-3’, 
reverse 5’-TTCTCTTCCGCACCCAGC-3’ and probes 5’-FAM-
CAGATTTTGGGCGGGCCAAAC-TAMRA-3’ and 5’-VIC-
TCACAGATTTTGGGCTGGCCAAAC-TAMRA-3’, as described by Rosell et al. (2008). 
The reaction was performed in the LightCycler®480 II Real-Time System [Roche Diagnostics] and 
samples were submitted to one cycle at 60°C for 1 minute, 95°C for 1 minute, 40 cycles of 
95°C for 15 seconds, 60°C for 1:30 minute with a quantification step and one cycle at 
95°C for 1 minute. All samples were performed in duplicate and the 96 well plate was 
sealed with sealing film and centrifuged at 1000 rpm for 1 minute. Results were analyzed 
with LightCycler® 480 Software [Roche Diagnostics] version 1.5.  
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3.5 KRAS Mutation Analysis 
3.5.1 HRM Analysis 
Amplification of KRAS exon 2 and HRM analysis were performed in 
LightCycler®480 II Real-Time System [Roche Diagnostics]. The primers [Frilabo] were as follows: 
forward 5’-TTATAAGGCCTGCTGAAAATGACTGAA-3’ and reverse 5’-
TGAATTAGCTGTATCGTCAAGGCACT-3’. The PCR reaction was performed with 1× 
LightScanner® Master Mix [Idaho], 0.15 µM of each primer [Frilabo], 50 ng of DNA and distilled 
water [B. Braun] in a total reaction volume of 10µl. To prevent evaporation or possible cross-
contamination, 15µl of mineral oil [Sigma] was added to all wells that contained reaction mix. 
All samples were analyzed in duplicated and plates were sealed with sealing film and 
centrifuged at 1000 rpm for 1 minute. The conditions for cycling and melting were the 
following: one cycle of 95°C for 15 minutes; 38 cycles of 95°C for 15 seconds, 69°C for 15 
seconds and 72°C for 15 seconds; an heterodulex step of 95°C for 1 minute and 40°C for 
1 minute; and a melt form 75°C to 90°C with 25 acquisitions per degree. 
Melt curve analysis was done using the LightCycler® 480 Software [Roche Diagnostics] 
version 1.5. A difference graph was used to differentiate between wild-type and samples 
with KRAS mutations. All samples classified as positive for KRAS exon 2 mutations or 
with a late amplification, were sequenced directly from the HRM product. 
 
3.5.2 DNA Sequencing 
The HRM products were purified with GFX PCR DNA and GEL Band Purification 
Kit [GE Healthcare Life Sciences], according to the manufacture’s protocol to remove salts, enzymes, 
nucleotides and non-incorporated primers. 
The sequencing reaction was performed in a 10 µl volume, adding 1 µl of 
Terminator Ready Reaction Mix [Applied Biosystems] (dNTP’s, ddNTP’s-fluorocromes, MgCl2 and 
Tris-HCl buffer), 1.9 µl of sequencing buffer [Applied Biosystems], 30 to 90 ng of purified DNA 
and 0.35 µM of primer. Primers [Frilabo] were forward 5’-GACTGAATATAAACTTGTGG-3’ 
and reverse 5’-CTATTGTTGGATCATATTCG-3’. The PCR reaction was carried out in a 
thermocycler and the program used was: an initial denaturation step at 96°C for 5 
minutes, followed by 35 cycles of denaturation at 96°C for 10 seconds, annealing at 52°C 
for 5 seconds and extension at 60°C for 4 minutes, and a final extension step at 72°C for 
5 minutes. 
The sequencing product was purified with IIlustra Sephadex® G-50 fine [GE Healthcare 
Life Sciences] columns to remove all contaminants. 
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The samples were eluted in 12µl of deionized formamide [Applied Biosystems] and 
sequencing analysis was carried out on an ABI PRISM 310 Genetic Analyzer [Applied 
Biosystems], where sequencing products were subjected to capillary electrophoresis. All 
electropherograms were analyzed by Sequencing Analysis Software v5.2 [Applied Biosystems]. 
 
3.6 ALK Analysis   
3.6.1 Immunohistochemistry (IHC) 
One hundred and forty four NSCLC FFPE tissues (of two hundred and seven total 
samples, forty-nine were from other hospitals so the paraffin block was not available, and 
fourteen were cytology), were sectioned at a thickness of 4 µm. Slides were 
deparaffinized in two passages through xylene and hydrated by a decreasing gradient of 
alcohols until 50% alcohol. Epitope retrieval was performed with pre-heated EDTA for 20 
minutes and all staining procedure was accomplished using NOVOLINK™ Max Polymer 
Detection System [Novocastra] according to the manufacture’s protocol. The antibody for ALK 
protein, Monoclonal Mouse Anti-Human CD246, ALK Protein - clones ALK [Dako], was 
diluted to 1:50 and incubated at room temperature for 1 hour. Antigen-antibody reaction 
was visualized trough 5 minutes incubation with diaminobenzidene (DAB) that was 
included in NOVOLINK™ Max polymer detection System [Novocastra]. Slide counterstaining 
was achieved with hematoxylin for 20 seconds at room temperature. The final step of the 
protocol was dehydration and the coverslipped slides were examined in a microscope. 
FFPE tissue from an anaplastic large T-cell lymphoma (ALCL) with ALK rearrangement 
was used as a positive control of the IHC reaction. 
 
3.6.2 Fluorescence In Situ Hybridization (FISH) 
FISH analyses for ALK rearrangements was performed in 4 µm thick FFPE tissue 
sections to confirm positive results obtained with IHC. Slides were deparaffinized by two 
passages through xylene, followed by other two passages through 100% alcohol, 5 
minutes each. For sample pre-treatment, slides were incubated in 2xSSC for 3 minutes, 
followed by incubation with NaSCN 1M at 80ºC for 10 minutes and 2xSSC for 2 minutes. 
The enzymatic digestion was performed through incubation with a pepsin solution (4mg/ml 
of pepsin mixed with 100 µl of HCl 1M plus 200 µl of ddH2O), with the tissue at 37ºC for 5 
minutes in the Hybrite [Vysis]. At the end of the incubation, the slides were placed in a 
2xSSC solution for 2 minutes, followed by an increasing gradient of alcohols, 70%, 85% 
and 100%, 2 minutes each. After the enzymatic digestion, slides were incubated with the 
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probes Vysis LSI ALK Dual Color, Break Apart Rearrangement Probe [Abbot Molecular] or 
ZytoLight® SPEC ALK/EML4 TriCheck™ Probe [ZYTOVISION] for 8 minutes at 80ºC, followed 
by 18 hours at 37ºC in the Hybrite system [Vysis]. Slides were then placed in 2xSSC/0.3% 
IGEPAL [Sigma-Aldrich] at 72ºC for 5 minutes, followed by a passage in 2xSSC/0.1% IGEPAL 
[Sigma-Aldrich] for 2 minutes. Hybridized slides were then stained with DAPI and examined 
with a fluorescence microscope [Zeiss Axioplan] coupled with a Cohu 4900 CCD camera and 
and the CytoVision software. FISH positive samples were defined by 15% or more of 100 
observed tumor cells with an ALK rearrangement. 
The first probe used was the Vysis LSI ALK Dual Color, Break Apart 
Rearrangement Probe [Abbot Molecular], where a spectrum-orange and a spectrum-green 
signal flank the 3’ and 5’ regions of ALK gene, respectively [Figure 13]. Since the most 
common ALK rearrangement results from a small inversion that might be difficult to 
visualize, we used the probe ZytoLight® SPEC ALK/EML4 TriCheck™ Probe [ZYTOVISION], 
which has a particular tri-color design: a spectrum-orange probe targets the ALK 3’ region, 
a spectrum-green probe targets the ALK 5’ region, and an additional spectrum-aqua probe 
targets the EML4 gene [Figure 14]. 
 
 
   
 
 
 
 
 
 
 
Figure 13 - Vysis LSI ALK Dual Color, Break Apart Rearrangement Probe [Abbot Molecular]. a) 
Ideogram with localization of the hybridization site of each probe in chromosome 2; b) Schematic 
representation of ALK break apart probe with discrimination of hybridization regions as well as their 
length (not to scale). The spectrum-orange probe has approximately 300 kb of length and 
hybridizes to the 3’ region of the gene that is oriented to the telomeric region of the chromosome. 
On the other side, the spectrum-green probe is slightly bigger (442 kb) and hybridizes to the 5’ 
region of ALK that is oriented to the centromere of the chromosome [adapted from: 
www.abbottmolecular.com]. 
 
According to the ZytoLight® SPEC ALK/EML4 TriCheck™ Probe [ZYTOVISION] protocol, in an 
interphase nucleus lacking ALK rearrangements the three probes appear co-localized. 
When an EML4-ALK fusion due to chromosome inversion is present, one should observe 
a) 
b) 
2 
SHGC-104192 
3’ 5’ 
ALK 
~300 
kb 
~442 kb 
2p23 Region 
SHGC-56576 
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one separate 3’ red signal and one separate 5’ green signal, each one co-localized with a 
smaller blue signal. Both the dual-color and the tri-color probes are able to detect also the 
less common ALK rearrangements caused by translocations. 
 
  
 
 
 
 
 
 
 
                         
 
 
  
 
Figure 14 - ZytoLight
®
 SPEC ALK/EML4 TriCheck
™
 Probe [ZYTOVISION]. a) Ideogram with 
localization of the hybridization site of ALK plus EML4 probes in chromosome 2; b) SPEC ALK 
probe map where the two probes are represented (not to scale). The spectrum-orange probe (~800 
kb) hybridizes distal to the ALK breakpoint region, whereas the spectrum-green probe (~650 kb) 
hybridizes proximal to the breakpoint region; c) SPEC EML4 probe map represents the probe that 
hybridizes to the entire EML4 gene. The probe shows a spectrum-aqua signal with approximately 
1.8 Mb [adapted from: www.immunologic.nl].  
 
3.7 Statistical Analysis 
The SPSS software version 17.0 was used for statistical analysis. The chi-square 
test was performed to access statistical differences between two groups of patients. 
Associations were considered statistically significant when p≤0.05. 
2 
a) 
b) 
c) 
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4. Results 
 
4.1 EGFR Exons 19 and 21 Analyses 
A consecutive series of DNA samples from NSCLC patients previously analyzed 
for EGFR mutations was studied. Fragment analysis and TaqMan SNP genotyping assay 
were performed for the detection of EGFR exon 19 deletions and the exon 21 
p.Leu858Arg mutation, respectively, and comparison with the currently used 
methodologies (HRM amplification/DNA sequencing) for EGFR routine genetic testing in 
the IPO-Porto Genetics Department. 
 
4.1.1 Fragment Analysis 
Of the total of 198 DNA samples, only 195 were analyzed by fragment analysis 
since three samples did not have sufficient amount of DNA. Of these, 169 samples 
(86.2%) were classified as negative for deletions in EGFR exon 19, whereas 16 samples 
(8.7%) were classified as positive [Figure 15]. The remaining samples, 10 in total (5.1%), 
could not be scored possibly due to poor DNA quality. The results are discriminated in 
Table 3, where the results are compared to those obtained by HRM amplification/DNA 
sequencing. 
 
 
Table 3 - Comparison of results between HRM amplification/DNA sequencing and fragment 
analysis, for EGFR exon 19 deletions. 
 
 EGFR exon 19 
deletions 
No EGFR exon 
19 deletions* 
ND (Not Done) Total samples 
HRM/DNA 
Sequencing 
16 179 ------------ 195 
Fragment Analysis 16 169 10 195 
 
*Including wild-type samples for EGFR exon 19 deletions and samples with other sort of EGFR mutations. 
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Figure 15 – EGFR exon 19 fragment analysis electropherogram. a) Negative sample for 
deletions in exon 19, which is characterized by the presence at only one peak close to the 120 bp 
position; b) Positive sample with a deletion in EGFR exon 19, which is characterized by the 
existence of two separated peaks, one close to 110 bp and a second close to 120 bp.  
 
4.1.2 TaqMan SNP Genotyping Assay 
A total of 188 samples (ten did not have the necessary amount of DNA) were 
analyzed by the TaqMan assay for detection of the point mutation p.Leu858Arg in EGFR 
exon 21. Of these, 161 (85.6%) were considered wild-type and five samples (2.7%) as 
positive. In the remaining 22 samples (11.7%), including four positive samples by HRM 
amplification/DNA sequencing, it was not possible to obtain results because DNA quality 
was poor.  
In Table 4 results related to the comparison between HRM amplification plus DNA 
sequencing and TaqMan assay are discriminated. Figure 16 illustrates the samples 
endpoint fluorescence scatter plot, according to VIC and FAM fluorochrome emission, 
which separates mutated from non-mutated samples. 
 
Table 4 - Comparison of EGFR exon 21 mutational status between HRM amplification/DNA 
sequencing and TaqMan assay. 
 
 EGFR exon 21 
p.Leu858Arg 
No EGFR exon 
21 p.Leu858Arg 
ND (Not Done) Total samples 
HRM /DNA 
Sequencing 
9 179 ------------ 188 
TaqMan Assay 5 161 22* 188 
 
*Includes four positive samples by HRM/DNA sequencing 
  
b) a) 
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Figure 16 – Endpoint fluorescence scatter plot of EGFR p.Leu858Arg point mutations. Near 
the y-axis (vertical axis), all negative samples for point mutations in exon 21 (green dots) are 
grouped. All samples which lied in the middle region (diagonal) of the plot were classified as 
positive samples (red dots). 
 
4.2 KRAS Mutation Analysis 
4.2.1 HRM Analysis 
A total of 198 DNA samples of NSCLC patients were screened for mutations in 
KRAS exon 2. Of these, 107 (54%) were considered KRAS wild-type and 32 (16.2%) 
KRAS positive. However, 59 cases (29.8%) could not be classified accurately due to late 
DNA amplification (starting from the 35th cycle of thirty-eight) [Figure 17].  
 
Figure 17 - Result of HRM analysis of KRAS exon 2. a) Normalized graphic; b) Difference 
graphic containing wild-type (blue lines), positive (green) and samples with late DNA amplification 
(red). 
 
a) b) 
Results 
54 
 
4.2.2 DNA Sequencing 
DNA sequencing was performed in cases considered to be positive by HRM and in 
59 samples with late amplification. Mutation identification was achieved in the 32 HRM 
positive samples, confirming the results of HRM and allowing mutation identification. Of 
the 59 samples with late amplification, 11 (18.6%) harbored mutations in KRAS exon 2, 
and the remaining 48 (81.4%) were classified as wild-type. In total, 43 samples (21.7%) 
harbored mutations in codons 12 or 13 of KRAS exon 2, including two samples each with 
two KRAS mutations and one sample with three KRAS mutations [Table 5; Figure 18; 
Appendix I]. 
Two KRAS-positive samples presented a concomitant mutation in the EGFR gene 
[Table 6], being both from women with adenocarcinoma and a mean age at diagnosis of 
61 years (only one presented information about the smoking status and was a smoker). 
One case presented a KRAS codon 12 transition in position 35 of a Gly to an Ala and a 
substitution of an Asp for a Tyr in position 2281 of exon 19 of EGFR. The second case 
harbored a transition of a Gly to an Asp in position 35 of KRAS codon 12 and the EGFR 
exon 21 point mutation p.Leu858Arg [Appendix I]. 
 
 
Table 5 – Discrimination of all point mutations found in 43 KRAS positive NSCLC. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HGVS Protein HGVS DNA Number of Cases Percentage 
p.Gly12Asp c.35G>A 14 32.6% 
p.Gly12Cys c.34G>T 12 28% 
p.Gly12Val c.35G>T 7 16.3% 
p.Gly13Asp c.38G>A 4 9.3% 
p.Gly12Ala c.35G>C 1 2.3% 
p.Gly13Cys c.37G>T 1 2.3% 
p.Gly12Ser c.34G>A 1 2.3% 
------------------ c.[34G>T(;)35G>T] 1 2.3% 
p.[Gly12Asp(;)Gly13Asp] c.[35G>A(;)38G>A] 1 2.3% 
------------------ c.[34G>T(;)35G>C(;)38G>A] 1 2.3% 
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Figure 18 – Electropherogram of all KRAS exon 2 point mutations (    ). a) Wild-type sample; 
b) c.35G>A; c) c.34G>T; d) c.35G>T; e) c.37G>T; f) c.34G>A; g) c.[34G>T(;)35G>T]; h) 
c.[35G>A(;)38G>A]; i) c.[34G>T(;)35G>C(;)38G>A].  
 
 
Table 6 – Characterization of the two samples with concomitant mutations in the KRAS and 
EGFR genes. 
 
 
Case 
Nº 
KRAS HGVS 
Protein 
KRAS HGVS 
DNA  
EGFR HGVS 
Protein 
EGFR HGVS 
DNA 
Age Gender 
Smoking 
Status 
Histology 
26 p.Gly12Ala c.35G>C p.Asp761Tyr 
c.2281G>T  
(exon 19) 
49 Female Smoker Adenocarcinoma 
98 p.Gly12Asp c.35G>A p.Leu858Arg 
c.2573T>G 
 (exon 21) 
73 Female -------- Adenocarcinoma 
b) 
d) 
e) f) 
c) 
c.12 c.13 a) 
h) g) 
i) 
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4.3 ALK Analysis 
4.3.1 Immunohistochemistry (IHC) 
A total of 144 samples were submitted to IHC for detection of ALK protein 
expression. Only one sample, case nº 22, (0.7%) showed a stained region, which, 
although not as intense as the positive ALCL control, represents abnormal overexpression 
of ALK in this sample type. [Figure 19a-c]. 
The positive sample belongs to a female patient with a lung adenocarcinoma, 
diagnosed at 74 years of age, negative for mutations in both EGFR and KRAS genes. IHC 
was additionally performed on a different tumor region of the positively stained tumor, to 
study eventual intratumor heterogeneity. Surprisingly, this other tumor area was negative 
for expression of the ALK protein by IHC [Figure 19d]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19 – Immunohistochemistry for detection of ALK protein expression. a) Positive 
control staining in an ALCL; b) Negative  NSCLC for ALK protein expression; c) Positive staining in 
a lung adenocarcinoma (Case nº22); d) Negative staining in a different tumoral region of the same 
patient as in c). 
 
4.3.2 Fluorescence In Situ Hybridization (FISH) 
FISH was used to confirm the results obtained by IHC in the tumor sample of case 
nº22. A specific signal configuration was found, namely, a 3’ red signal co-localized with a 
5’ green signal (representing the normal ALK gene), plus a 3’ red signal separated from a 
5’ green signal and an extra copy of the 3' red signal, which was defined as a clonal 
pattern since it appeared in all tumor cells [Figure 20 a]. However, in the majority of tumor 
c) d) 
a) b) 
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cells, besides the presence of the clonal pattern, several additional probe signals were 
observed, presumably representing chromosomal instability.  
 
 
 
 
 
 
 
 
Figure 20 – FISH patterns indicative of ALK rearrangement using the ALK break-apart probe 
in case nº22. a) Neoplasic cell with the main clonal pattern; b) Besides the presence of the clonal 
pattern, this cell presents in addition one extra copy of the isolated 3’ red signal and one extra copy 
of the co-localized 3’ red/5’ green signals. 
 
When the IHC positive sample was hybridized with the tri-color probe, a very 
similar result was observed. The established ALK break-apart clonal pattern was also 
observed, but in this case it was a 3’ red signal co-localized with a 5’ green signal and a 
blue signal (the normal ALK gene), a 3’ red signal co-localized with a blue signal, a 5’ 
green signal co-localized with a blue signal and an extra copy of a 3’ red signal co-
localized with a blue signal. Besides the presence of the clonal pattern, chromosomal 
instability was also observed with this probe [Figure 21]. 
 
 
 
 
 
 
 
 
 
 
The additional tumor sample from a different tumor area of case nº22, which 
turned out to be negative for ALK expression by IHC, was hybridized with the tri-color 
probe and presented a FISH pattern very similar to that observed in the initial tumor 
sample overexpressing ALK [Figure 22], therefore demonstrating their clonal relationship. 
 
a) b) 
b) 
Figure 21 – FISH pattern indicative of an EML4-ALK 
fusion gene using the tri-color probe in case nº22. 
Rearranged cell with the EML4-ALK fusion, where the 
clonal pattern is visible together with several extra copies 
of 3’ red, 5’ green and blue signals. 
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4.4 Statistical Analysis 
4.4.1 EGFR TKI Sensitizing Mutations 
At the time of writing, clinicopathological features were only available for a 
proportion of the 184 patients analyzed for EGFR exon 19 deletions and exon 21 
p.Leu858Arg by fragment analysis and the Taqman assay. The qui-square test was used 
to assess differences between cases with EGFR wild-type and TKI sensitizing mutations 
regarding clinicopathological variables, such as age at diagnosis [Table 7], gender [Table 
8], smoking status [Table 9] and NSCLC histology [Table 10]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Age at Diagnosis 
n= 137 
EGFR Gene 
Total 
Wild-Type Mutant 
<60 years 40 2 42 
≥60 years 81 14 95 
Total 121 16 137 
Chi-Square Test p= 0.094 
Gender 
n= 184 
EGFR Gene 
Total 
Wild-Type Mutant 
Female 34 16 50 
Male 128 6 134 
Total 162 22 184 
Chi-Square Test p= 0.00 
Figure 22 – FISH pattern indicative of an EML4-
ALK fusion with the tri-color probe from a 
different tumor area of case nº22. Rearranged cell 
with the EML4-ALK rearrangement and also several 
extra copies of 3’ red, 5’ green and blue signals. 
Table 7 - Distribution of EGFR TKI sensitizing mutations 
according to patient age. 
Table 8 - Distribution of EGFR TKI sensitizing mutations 
according to patient gender. 
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Comparing patient’s age at diagnosis, gender, smoking status and NSCLC 
histology with EGFR status, no significant differences were obtained: 4.8% in <60 years 
vs. 14.7% in ≥60 years (p= 0.094); 2.3% in former smokers vs. 4.5% in current smokers 
(p= 0.570); 15.7% in adenocarcinomas vs. 6.8% in other histological types, such as 
squamous cell, large cell, adenosquamous and mix pattern carcinoma (adenocarcinoma 
component associated with a large cell carcinoma component) (p= 0.099), respectively. 
On the other hand, the frequency of EGFR TKI sensitizing mutations differ by gender (p= 
0.00), being significantly more frequent in women (32%) than in men (4.4%). 
 
 
 
 
 
 
 
 
 
 
 
Smoking Status 
n= 87 
EGFR Gene 
Total 
Wild-Type Mutant 
Former Smoker 42 1 43 
Current Smoker 42 2 44 
Total 84 3 87 
Chi-Square Test p= 0.570 
NSCLC Histology 
n= 179 
EGFR Gene 
Total 
Wild-Type Mutant 
Adenocarcinoma 102 19 121 
Other Types 54 4 58 
Total 156 23 179 
Chi-Square Test p= 0.099 
Table 9 - Distribution of EGFR TKI sensitizing mutations 
according to patient smoking status. 
Table 10 - Distribution of EGFR TKI sensitizing mutations 
according to patient NSCLC histology. 
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4.4.2 KRAS Mutations 
Clinicopathological features were only available for a proportion of the 198 cases 
at the time of writing, as indicated in Tables 7, 8, 9 and 10. The qui-square test was used 
to assess differences in KRAS statusand clinicopathological variables, such as age at 
diagnosis [Table 11], gender [Table 12], smoking status [Table 13] and NSCLC histology 
[Table 14].  
 
 
 
 
 
 
 
 
When comparing patient’s age at diagnosis, gender and smoking status with 
KRAS mutations, no significant differences were obtained: 20.8% in <60 years vs. 23.9% 
in ≥60 years (p= 0.364); 13.8% in women vs. 25% in men (p= 0.082); 23.4% in former 
smokers vs. 28.2% in current smokers (p= 0.593). On the other hand, KRAS mutations 
were more frequent in adenocarcinomas (28.3%) than in other histological types, such as 
squamous cell, large cell, adenosquamous and mix pattern carcinomas (adenocarcinoma 
component associated with a large cell carcinoma component) (7.6%) (p= 0.001).  
 
Age at Diagnosis 
n=144 
KRAS Gene 
Total 
Wild-Type Mutant 
<60 years 38 10 48 
≥60 years 73 23 96 
Total 111 33 144 
Chi-Square Test p= 0.364 
Gender 
n=198 
KRAS Gene 
Total 
Wild-Type Mutant 
Female 50 8 58 
Male 105 35 140 
Total 155 43 198 
Chi-Square Test p= 0.082 
NSCLC Histology 
n=193 
KRAS Gene 
Total 
Wild-Type Mutant 
Adenocarcinoma 91 36 127 
Other Types 61 5 66 
Total 152 41 193 
Chi-Square Test p= 0.001 
Smoking Status 
n=93 
KRAS Gene 
Total 
Wild-Type Mutant 
Former Smoker 36 11 47 
Current Smoker 33 13 46 
Total 69 24 93 
Chi-Square Test p= 0.593 
Table 11 - Distribution of KRAS exon 2 
mutations according to patient age. 
Table 12 - Distribution of KRAS exon 2 
mutations according to patient gender. 
Table 13 – Distribution of KRAS exon 2 
mutations according to patient smoking status. 
Table 14 – Distribution of KRAS exon 2 
mutations according to NSCLC histology. 
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5. Discussion 
 
The NSCLC tumor sample series of the IPO-Porto Genetics Department includes a 
significant proportion of biopsies or cytology specimens, which allow a smaller cellular 
representation of the tumor, but also larger FFPE tumor samples. Therefore, in several 
minute samples, there was not enough DNA of good quality or additional tumor tissue to 
allow testing and comparison of all methodologies included in this study. This sample 
series also includes a large proportion of adenocarcinomas, since this NSCLC histological 
type is preferentially referred for detection of EFGR gene mutations as predictive markers 
for TKI therapy. These caveats notwithstanding, this study allowed the characterization of 
the mutational pattern of EGFR, KRAS, and ALK in a significant series of Portuguese 
NSCLC with a combination of different methodologies. The standard methodology in use 
at the IPO-Porto Genetics Department to detect mutations in the EGFR gene relies on an 
initial DNA amplification through HRM, followed by DNA sequencing. Using these 
techniques, 16 EGFR class I mutations (exon 19 deletions), 10 class II mutations (nine 
p.Leu858Arg and one p.Leu861Gln), one class III mutation (p.Asn771_His773dup) one 
p.Gly735Ser point mutation in EGFR exon 19, and a concomitance between a 
p.Gly735Ser in exon 19 and a p.Pro848Ser in exon 21, were detected (Eberhard et al., 
2005; Shigematsu and Gazdar, 2006; Mitsudomi and Yatabe, 2007; Sharma et al., 2007; 
Gazdar, 2009). Fragment analysis and the TaqMan SNP genotyping assay were 
evaluated for detection of the EGFR exon 19 deletions and exon 21 p.Leu858Arg, 
respectively, and to compare the findings with those obtained by currently used 
methodologies in the IPO-Porto Genetics Department. A study conducted by Molina-Vila 
and colleagues (2006) described these two specific techniques, which allow the detection 
of EGFR mutations in samples containing as few as eight cancer cells.  
Concerning the screening of EGFR exon 19 deletions, we verified that fragment 
analysis detected all deletions previously identified by HRM amplification/DNA 
sequencing. As expected, two additional exon 19 mutations were not detected by this 
technique, since they are missense mutations (p.Gly735Ser, p.Asp761Tyr). As described 
by Molina-Vila and colleagues (2006), fragment analysis only detects alterations that 
confer a molecular weight variation, like deletions or insertions, and for this reason other 
kinds of exon 19 mutations, like single base transition, are not detected by this technique. 
Regarding the TaqMan SNP genotyping assay for the mutation p.Leu858Arg, the results 
were also similar to those obtained by HRM amplification/DNA sequencing. Of the total 
number of nine samples with the p.Leu858Arg mutation, all five cases with sufficient DNA 
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were classified as mutation positive by the TaqMan assay analysis. This methodology to 
screen the p.Leu858Arg exon 21 mutation relies on the fact of combining internal probes, 
labeled with fluorescent dyes, to standard PCR amplification primers, allowing the 
detection of specific amplification products only (Stults et al., 2001; Molina-Vila et al., 
2006). We therefore conclude that fragment analysis and the TaqMan assay are two fast 
and relatively cheap alternatives to detect the two most common types of EGFR 
sensitizing mutations. On the other hand, no additional such mutations were identified 
when compared with HRM amplification/DNA sequencing routine analysis, therefore 
indicating that the two strategies have similar sensitivities to screen for these specific 
mutation types. On the other hand, if one wants to identify other mutation types in EGFR 
exons 18-21, be they TKI sensitizing or associated with TKI resistance, one would still 
need a more general screening methodology like HRM amplification/DNA sequencing.  
In the literature, 20-40% of NSCLC tumors present mutations in the KRAS gene, of 
which 80-90% occur in exon 2 codon 12 and 10% in exon 2 codon 13 (Keohavong et al., 
1996; Krypuy et al., 2006; Sakuma et al., 2007; Camps et al. 2010; Okudela et al., 
2010;Sanders and Albitar, 2010; van Eijk et al., 2010). In order to evaluate the KRAS 
mutation frequency and pattern in Portuguese NSCLC, as well as their presumed mutual 
exclusivity with EGFR mutations, we analyzed the 198 tumors with available DNA. In this 
work, 21.7% of the samples harbored mutations in KRAS exon 2, of which 88.6% 
occurred in codon 12 and 11.4% in codon 13. Codon 12 most frequent point mutations 
were p.Gly12Asp, p.Gly12Cys and p.Gly12Val, whereas in codon 13 it was p.Gly13Asp 
followed by p.Gly13Cys.  
Two NSCLC showed concomitant EGFR and KRAS mutations. This is in line with 
earlier reports (Eberhard et al., 2005; Han et al., 2006; Zhu et al., 2008; Benesova et al., 
2010; Smits et al., 2012), and it has been estimated that the probability of detecting EGFR 
and KRAS alterations in the same NSCLC tumor is of 1-3% (Greenman et al., 2006). One 
of the patients with concomitant EGFR/KRAS mutations had a point mutation in exon 19 
of EGFR, p.Asp761Tyr, and a point mutation in codon 12 of KRAS, p.Gly12Ala. The 
second such tumor had a point mutation in exon 21 of EGFR, p.Leu858Arg, and a point 
mutation in codon 12 of KRAS, p.Gly12Asp, a combination that was also described in the 
study of Benesova and colleagues (2010). Both NSCLC patients were women with 
metastatic adenocarcinomas, being at least one of them associated with smoking. 
The p.Asp761Tyr EGFR exon 19 mutation was previously found in a brain lesion of 
a NSCLC patient, who developed brain metastasis late in the course of gefitinib treatment 
(Balak et al., 2006), and seems to be associated with TKI drug resistance (Sharma et al., 
2007). When in concomitance with the EGFR p.Leu858Arg mutation, this missense exon 
19 mutation decreases the TKI sensitivity usually associated with that exon 21 point 
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mutation (Balak et al., 2006; Ichihara et al., 2007; Toyooka et al., 2007). Some studies 
suggest a “gain-of-function” property of the p.Asp761Tyr mutant that may confer a 
biological aggressiveness to the tumor, although how this mutation affects the EGFR 
kinase domain remains to be determined (Balak et al., 2006; Toyooka et al., 2007). The 
analysis of the cristal structure of the EGFR kinase domain bound to the TKI drug predicts 
that this exon 19 point mutation occurs in the α-C-helix of EGFR, adjacent to a well-
conserved glutamic acid residue at position 762, which, together with Lys745, forms a salt 
bridge that interacts with the α- and β-phosphates when ATP is present (Stamos et al., 
2002; Balak et al., 2006). Mutations occurring in the α-C-helix of other tyrosine kinases 
targeted by TKI have been reported in patients with acquired resistance (Balak et al., 
2006). In addition to EGFR p.Asp761Tyr, tumor case nº26 also harbored a point mutation 
in KRAS codon 12 (p.Gly12Asp). Although KRAS mutations are oncogenic events in 
NSCLC carcinogenesis (Massion and Carbone, 2003; Cherneva et al., 2007; Sanders and 
Albitar, 2010), which may be responsible for disease progression especially during 
therapy with gefitinib (Ji et al., 2007), it is believed that different KRAS mutations may lead 
to different signal transduction cascade in NSCLC and, therefore, to partially different 
carcinogenic pathway and drug sensitivity (Garassino et al., 2011). However, the 
p.Gly12Ala mutation does not have functional studies confirming its biological function in 
NSCLC (COSMIC). According to a study by Oliveira et al. (2007) in microsatellite-stable 
colorectal carcinoma, KRAS activation is likely to confer to tumor cells a more invasive 
behavior, increasing the ability of tumor cells to invade and progress through the epithelial 
basement membrane. Based on these findings, the presence of p.Gly12Ala may be 
considered as a primary event conferring a more invasive behavior to the tumor, whereas 
p.Asp761Tyr might be classified as a secondary event appearing only after NSCLC 
metastization. 
The second case (case nº98) with concomitant EGFR/KRAS mutations presents a 
EGFR p.Leu858Arg exon 21 mutation that is, not only a class II activating mutation, but 
also a TKI sensitizing mutation (Sharma et al. 2007; Gazdar et al., 2009). On the other 
hand, the concomitant KRAS codon 12 mutation p.Gly12Asp has an unknown biological 
function in NSCLC (COSMIC). In this sample, two different scenarios could be 
considered: each mutation took place in different tumor clones, or both mutations occur in 
the same clone at different time points. The first scenario, observed in the studies of Han 
et al. (2006) and Benesova et al. (2010), would indicate the polyclonal nature of this lung 
tumor through the existence of a subpopulation with a TKI sensitizing EGFR mutation 
(p.Leu858Ar), as well as another subpopulation with a KRAS mutation (p.Gly12Asp). TKI 
treatment in such cases could result in a partial response until the TKI-sensitive 
subpopulation (p.Leu858Arg) eventually disappears and only the TKI-resistant 
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subpopulation (p.Gly12Asp) remains (Benesova et al., 2010). The second scenario 
postulates the p.Leu858Arg EGFR mutation as the primary event and the occurrence of 
the p.Gly12Asp KRAS mutation as a mechanism of disease progression leading to a 
metastatic NSCLC resistant to TKI therapy.   
Several recent reports showed that NSCLC patients with ALK-positive tumors 
respond to crizotinib, a TKI specifically designed to interact directly with the tyrosine 
kinase domain of the ALK protein (Kwak et al., 2010; Ou et al., 2010; Camidge et al., 
2011; Crinò et al., 2011; Ou, 2011; National Comprehensive Cancer Network, 2012). In 
this work, detection of ALK protein expression was performed in 144 samples by IHC and 
an ALK rearrangement was confirmed by FISH. Selection of IHC as an initial methodology 
to detect ALK rearrangements is justified because it is an easy and relatively inexpensive 
analysis in a setting where the ALK rearrangement frequency is relatively low (Jokoji et 
al., 2010; Mino-Kenudson et al., 2010; Sasaki et al., 2010). In fact, IHC identified a single 
case (case nº22) in 144 that did express the ALK protein, namely, an adenocarcinoma 
negative for mutations in both EGFR and KRAS genes in a 74-year-old woman. However, 
ALK expression in lung carcinomas with ALK rearrangements is known to be weaker than 
those occurring in ALCL, here used as positive control. This is possibly related to a weak 
transcriptional activity of EML4 in NSCLC when compared with the transcriptional activity 
of ALK fusion partners in ALCL, resulting in lower level of ALK protein expression in ALK-
rearranged NSCLC compared to ALK-rearranged ALCL (Takeuchi et al., 2009; Mino-
Kenudson et al., 2010; Sasaki et al., 2010).  
The presence of an ALK rearrangement in this case was confirmed by FISH, a 
more sensitive and specific, although more expensive, methodology. FISH allows the 
detection of ALK rearrangements with specific probes flanking this gene, as well as 
eventual identification of the ALK fusion partner (Shaw et al., 2009; Sasaki et al., 2010; Yi 
et al., 2011). Using two different probes, an ALK break-apart probe and an EML4-ALK tri-
color probe, it was possible to identify the EML4-ALK fusion gene as the primary event in 
this tumor and to identify a clonal pattern that was shared by the majority of NSCLC tumor 
cells. However, some tumor subpopulations presented more complex FISH patterns, with 
several extra copy signals of the 3’ red, 5’ green and blue probes. These extra signals are 
most likely secondary events resulting from chromosomal instability, which may result in 
clonal evolution and contribute to the complex karyotypes often present in NSCLC 
(Doebele et al., 2012).   
Having confirmed ALK positivity in a single NSCLC, we decided to look for 
possible intratumor heterogeneity regarding ALK genetic rearrangement and/or ALK 
expression by IHC. Surprisingly, a different tumor area from the initially analyzed case 
nº22 was classified as negative for ALK protein expression by IHC, whereas the ALK 
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rearrangement by FISH was present there as well. The discrepancy in the IHC results 
may be related to intratumor heterogeneity regarding ALK protein expression. This 
discrepancy between IHC and FISH results reinforces the idea that FISH is more sensitive 
and specific than IHC to identify ALK rearrangements even in samples with a low 
representation of tumor cells or with weak protein expression. There have been attempts 
to improve IHC sensitivity, namely by the use of highly sensitive antibodies (Mino-
Kenudson et al., 2010) and/or implementation of a more sensitive IHC protocol called 
intercalated antibody-enhanced polymer (iAEP) (Hernández et al., 1999; Takeuchi et al., 
2009; Jokoji et al., 2010; Sasaki et al., 2010; Togashi et al., 2012). Nevertheless, as there 
is a significant cost difference between IHC and FISH and the ALK rearrangement 
frequency is only about 1%, the best strategy to implement ALK rearrangement screening 
is to start with IHC analysis, having in mind the potential intratumor heterogeneity in larger 
tumors, and all samples with a positive or doubtful staining being afterwards submitted to 
FISH analyses to confirm the presence of an ALK rearrangement. 
According to the literature, EGFR TKI sensitizing mutations in NSCLC patients are 
more frequent in Asians, women, non-smokers and in adenocarcinomas (Mitsudomi and 
Yatabe, 2007; Laurent-Puig et al., 2009; Rosell et al., 2009; Suda et al., 2010; Gaughan 
and Costa, 2011). The present study confirms the association between the most common 
EGFR mutations and the female gender. Other clinicopathological associations were not 
statistically significant in this study, although some showed a tendency in the expected 
direction, something that might be due to a relatively small sample size coupled with the 
absence clinical data for several NSCLC patients. On the other hand, some 
clinicopathological features have been associated with KRAS mutations in NSCLC, 
namely male patients, Caucasians, former/current smokers and adenocarcinoma 
histology are more likely to present KRAS mutations (Riely et al., 2008; Riely et al., 2009). 
The present study showed a statistically significant association between KRAS mutations 
and adenocarcinomas compared with other histological types, a finding that is consistent 
with that of others (Riely et al., 2008; Riely et al., 2009; Smits et al., 2012). Again, other 
clinicopathological associations reported in the literature (Tam et al., 2006; Li et al., 2009) 
were not statistically significant in this study, most likely for the same reasons alluded to 
above.   
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6. Conclusion 
 
Taking into account the results obtained in this study, we can conclude: 
 
 The results from fragment analysis and TaqMan SNP genotyping assay 
were the same as those obtained by HRM amplification/DNA sequencing 
for the common EGFR exom 19 deletions and the p.Leu858Arg mutation 
(10%). The routine diagnostic methodology did not show any false 
negatives and in addition is able to detect other mutations in EGFR exons 
18, 19, 20 and 21; 
 The frequency of KRAS mutations in Portuguese NSCLC was 21.7% 
(88.4% in codon 12 and 11.6% in codon 13), which is in accordance to the 
literature from other regions; 
 EGFR/KRAS concomitant mutations may occur in about 1% of the 
samples, but mutual exclusivity of primary genetic changes in lung 
carcinogenesis is the general rule; 
 The strategy of initial IHC screening followed by FISH analysis to identify 
NSCLC with ALK rearrangements was validated, although care should be 
taken to analyze different tumor areas by IHC to account for eventual 
intratumor heterogeneity in ALK expression. 
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7. Future Perspectives  
 
 IHC of different areas of 22 NSCLC tumors with more than one paraffin 
block, and confirmation of the result by FISH; 
 
 Optimization of RT-PCR protocol for detection of ALK fusion transcripts in 
FFPE tissue samples; 
 
 Identification/confirmation of the fusion partner of the ALK gene in FISH 
positive tumors. 
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Appendix I 
 
Discrimination of the mutational status of EGFR, KRAS and ALK in 207 NSCLC samples. 
Cas
e Nº 
 
EGFR exon 19 Deletions 
EGFR exon 21 
p.Leu858Arg 
KRAS Mutations 
ALK 
Rearrangem
ents 
HGVS Protein HGVS DNA 
HGVS 
Protei
n 
HGV
S 
DNA 
HGVS Protein HGVS DNA IHC FISH 
1 ND ND ND ND ND ND ND ND 
2 ND ND ND ND ND ND ND ND 
3 ND ND ND ND ND ND ND ND 
4  wt wt  wt  wt  wt  wt  ND ND 
5 ND ND ND ND ND ND ND ND 
6  wt wt  wt  wt  wt  wt   Neg Neg 
7 ND ND ND ND  wt  wt ND ND 
8  wt wt  wt  wt  wt  wt   Neg Neg 
9  wt wt  wt  wt  p.Gly12Cys   c.34G>T ND ND 
10  wt wt  wt  wt  wt  c.[34G>t(;)35
G>T] 
 Neg Neg 
11 p.Leu747_Ala750
delinsPro 
c.2238_2248 
delinsGC 
 Neg Neg  wt wt   Neg Neg 
12  wt wt  wt  wt  p.Gly12Cys   c.34G>T  Neg Neg 
13  Neg Neg p.Leu8
58Arg 
c.257
3T>G 
 wt wt   Neg Neg 
14  wt wt  wt  wt  wt  wt   Neg Neg 
15  wt wt  wt  wt  wt  wt   Neg Neg 
16  wt wt  wt  wt  wt  wt   Neg Neg 
17 wt wt ND ND  wt wt   Neg Neg 
18  wt wt  wt  wt  wt  wt   Neg Neg 
19 ND ND ND ND ND ND ND ND 
20  wt wt  wt  wt  wt  wt   Neg Neg 
21  wt wt  wt  wt  wt  wt  ND ND 
22  wt wt  wt  wt  wt  wt  Posi
tive 
Posi
tive 
23  wt wt  wt  wt  wt  wt   Neg Neg 
24  wt wt  wt  wt  p.Gly12Asp  c.35G>A  Neg Neg 
25  wt wt  wt  wt  p.Gly12Cys  c.34G>T   Neg Neg 
26 Neg 
(p.Asp761Tyr) 
Neg 
(c.2281G>T) 
 Neg Neg p.Gly12Val  c.35G>C  Neg Neg 
27  wt wt   wt wt   wt wt   Neg Neg 
28 p.Leu747_Ala750
delinsPro 
c.2239_2248 
delinsC 
 Neg Neg  wt wt   Neg Neg 
29  wt wt  wt  wt  wt  wt   Neg Neg 
30 wt wt ND ND  wt wt   Neg Neg 
31  wt wt  wt  wt  wt  wt   Neg Neg 
32  wt wt  wt  wt  wt  wt   Neg Neg 
33  Neg Neg  Neg  Neg  wt  wt   Neg Neg 
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34  wt wt  wt  wt  wt  wt  ND ND 
35 p.Glu746_Ala750
del 
c.2236_2250del  Neg Neg wt  wt   Neg Neg 
36  wt wt  ND ND p.Gly12Asp  c.35G>A ND ND 
37  wt wt  wt wt  wt wt   Neg Neg 
38  wt wt   wt wt  wt  wt  ND ND 
39  wt wt   wt wt  wt  wt   Neg Neg 
40  wt wt   wt wt  p.Gly12Val  c.35G>T  Neg Neg 
41  wt wt   wt wt   wt wt   Neg Neg 
42 p.Glu746_Thr751
delinsIle 
c.2237_2253 
delinsAT 
 Neg Neg  wt wt   Neg Neg 
43  wt wt  wt  wt  wt  wt   Neg Neg 
44  wt wt  wt  wt  wt  wt   Neg Neg 
45  wt wt  wt  wt  wt  wt   Neg Neg 
46  wt wt  wt  wt  p.Gly12Asp  c.35G>A  Neg Neg 
47  wt wt  wt  wt  wt  wt   Neg Neg 
48  wt wt  wt  wt  wt  wt   Neg Neg 
49  wt wt  wt  wt  wt  wt   Neg Neg 
50  wt wt  wt  wt  wt  wt  ND ND 
51  wt wt  wt  wt  wt  wt  ND ND 
52  wt wt  ND ND p.[Gly12Asp(;)Gly
13Asp] 
c.[35G>A(;)38
G>A] 
ND ND 
53 p.Glu746_Ser752
delinsVal 
c.2237_2255 
delinsT 
 Neg Neg wt  wt   Neg Neg 
54  wt wt  wt  wt  wt  wt   Neg Neg 
55  wt wt  wt  wt  wt  wt   Neg Neg 
56  wt wt  wt  wt  wt  wt   Neg Neg 
57  wt wt  wt  wt  wt  wt   Neg Neg 
58  wt wt  wt  wt  wt  wt  ND ND 
59  wt wt  wt  wt  wt  wt   Neg Neg 
60  wt wt  wt  wt  wt  wt   Neg Neg 
61  wt wt  wt  wt  wt  wt   Neg Neg 
62  wt wt  wt  wt  p.Gly12Cys  c.34G>T  Neg Neg 
63  wt wt  wt  wt  wt  wt   Neg Neg 
64  wt wt  wt  wt  wt  wt   Neg Neg 
65 ND ND ND ND ND ND ND ND 
66 ND ND ND ND ND ND ND ND 
67  wt wt  wt  wt  wt  wt   Neg Neg 
68  wt wt  wt  wt  wt  wt   Neg Neg 
69  wt wt  wt  wt  p.Gly12Cys   c.34G>T  Neg Neg 
70  wt wt  wt  wt   wt wt   Neg Neg 
71  wt wt  wt  wt  p.Gly12Asp  c.35G>A  Neg Neg 
72  wt wt  wt  wt   wt wt   Neg Neg 
73  wt wt  wt  wt   wt wt   Neg Neg 
74 ND ND ND ND p.Gly12Val  c.35G>T ND ND 
75  wt wt  wt  wt  wt  wt  ND ND 
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76  wt wt  ND ND p.Gly13Asp  c.38G>A ND ND 
77  wt wt   wt wt  p.Gly13Asp   c.38G>A  Neg Neg 
78  wt wt   wt wt  p.Gly12Asp  c.35G>A  Neg Neg 
79  Neg Neg p.Leu8
58Arg 
c.257
3T>G 
 wt wt  ND ND 
80  wt wt  wt  wt  wt  wt   Neg Neg 
81 p.Glu746_Ala750
del 
c.2235_2249del  Neg Neg  wt wt   Neg Neg 
82  wt wt  wt  wt  wt  wt   Neg Neg 
83  wt wt  wt  wt  wt  wt   Neg Neg 
84  wt wt  wt  wt  wt  wt  ND ND 
85  wt wt  wt  wt  p.Gly12Cys   c.34G>T  Neg Neg 
86 p.Leu747_Ala755
delinsSerLysAsp 
c.2240_2265deli
nsCGAAAGAT) 
 Neg Neg wt  wt  ND ND 
87  wt wt  wt  wt  wt  wt   Neg Neg 
88  wt wt  wt  wt  wt  wt  ND ND 
89  wt wt  wt  wt  wt  wt   Neg Neg 
90  wt wt  wt  wt  wt  wt   Neg Neg 
91  Neg Neg Neg Neg wt  wt   Neg Neg 
92  wt wt  wt  wt  p.Gly12Cys  c.34G>T   Neg Neg 
93  wt wt  wt  wt  wt  wt   Neg Neg 
94  wt wt  wt  wt  wt  wt   Neg Neg 
95 wt wt wt wt  wt wt   Neg Neg 
96  wt wt  wt  wt  wt  wt   Neg Neg 
97  wt wt  ND ND  wt wt  ND ND 
98  Neg Neg p.Leu8
58Arg 
c.257
3T>G 
p.Gly12Asp  c.35G>A  Neg Neg 
99 wt wt ND ND  wt wt   Neg Neg 
100  wt wt  wt  wt  wt  wt   Neg Neg 
101  wt wt  wt  wt  wt  wt   Neg Neg 
102  wt wt  wt  wt  wt  wt   Neg Neg 
103  wt wt  wt  wt  wt  wt   Neg Neg 
104  wt wt  wt  wt  p.Gly12Cys   c.34G>T  Neg Neg 
105  wt wt  wt  wt  wt  wt   Neg Neg 
106  wt wt  wt  wt  wt  wt  ND ND 
107  wt wt  wt  wt  p.Gly12Val  c.35G>T ND ND 
108  wt wt  wt  wt  wt  wt   Neg Neg 
109  wt wt  wt  wt  wt  wt   Neg Neg 
110  wt wt  wt  wt  p.Gly12Val  c.35G>T  Neg Neg 
111  wt wt  ND ND  wt wt   Neg Neg 
112  wt wt  wt  wt  p.[Gly12Cys(;)Gly
12Val(;)Gly13Asp ]  
c.[34G>T(;)35
G>T(;)38G>A] 
ND ND 
113  wt wt  wt  wt  wt  wt   Neg Neg 
114  wt wt  wt  wt  wt  wt   Neg Neg 
115 p.Glu746_Ala750
del 
c.2236_2250del  Neg Neg  wt wt   Neg Neg 
116 p.Glu746_Ala750
del 
c.2235_2249del  Neg Neg wt  wt  ND ND 
117  wt wt  wt  wt  wt  wt   Neg Neg 
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118  wt wt  wt  wt  wt  wt  ND ND 
119  wt wt  wt  wt  wt  wt   Neg Neg 
120  wt wt  wt  wt  wt  wt   Neg Neg 
121  wt wt  wt  wt  wt  wt  ND ND 
122  wt wt  wt  wt  wt  wt   Neg Neg 
123  wt wt  wt  wt  wt  wt   Neg Neg 
124  wt wt  wt  wt  wt  wt   Neg Neg 
125  wt wt  ND ND  wt wt   Neg Neg 
126  wt wt   wt wt  wt  wt   Neg Neg 
127  wt wt   wt wt  wt  wt  ND ND 
128  wt wt   wt wt  wt  wt   Neg Neg 
129  wt wt   wt wt  wt  wt   Neg Neg 
130  wt wt   wt wt  p.Gly13Asp   c.38G>A ND ND 
131  wt wt   wt wt   wt wt   Neg Neg 
132  wt wt   wt wt  p.Gly12Asp  c.35G>A  Neg Neg 
133  wt wt   wt wt   wt wt   Neg Neg 
134  wt wt   wt wt   wt wt   Neg Neg 
135  wt wt   wt wt  p.Gly12Cys   c.34G>T  Neg Neg 
136  wt wt   wt wt  p.Gly12Cys  c.34G>T   Neg Neg 
137  wt wt  wt  wt  wt  wt   Neg Neg 
138  wt wt  wt  wt  wt  wt   Neg Neg 
139  wt wt  wt  wt  p.Gly12Val  c.35G>T  Neg Neg 
140  wt wt  wt  wt  p.Gly12Asp  c.35G>A  Neg Neg 
141  wt wt  wt  wt   wt wt  ND ND 
142  wt wt  wt  wt   wt wt  ND ND 
143  wt wt  wt  wt   wt wt  ND ND 
144  wt wt  wt  wt  p.Gly13Cys  c.37G>T ND ND 
145  wt wt  wt  wt   wt wt   Neg Neg 
146  wt wt  wt  wt   wt wt   Neg Neg 
147  wt wt  wt  wt   wt wt   Neg Neg 
148  wt wt  ND ND p.Gly13Asp  c.38G>A  ND ND 
149  wt wt   wt wt  wt  wt   Neg Neg 
150  wt wt   wt wt  wt  wt   Neg Neg 
151 p.Leu747_Thr751
del  
c.2240_2254del  Neg Neg  wt wt  ND ND 
152  wt wt  wt  wt  wt  wt   Neg Neg 
153  wt wt  wt  wt  wt  wt  ND ND 
154  wt wt  wt  wt  wt  wt   Neg Neg 
155  wt wt  wt  wt  wt  wt   Neg Neg 
156  wt wt  wt  wt  p.Gly12Val  c.35G>T  Neg Neg 
157  wt wt  wt  wt   wt wt  ND ND 
158  wt wt  wt  wt   wt wt   Neg Neg 
159  Neg Neg p.Leu8
58Arg 
c.257
3T>G 
 wt wt  ND ND 
160 p.Leu747_Ala750
delinsPro 
c.2239_2248 
delinsC 
 Neg Neg  wt wt  ND ND 
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161  wt wt  wt  wt  wt  wt   Neg Neg 
162  wt wt  wt  wt  wt  wt   Neg Neg 
163  wt wt  wt  wt  wt  wt   Neg Neg 
164  wt wt  wt  wt  p.Gly12Val  c.35G>T  Neg Neg 
165  wt wt  wt  wt  p.Gly12Cys   c.34G>T ND ND 
166  wt wt  wt  wt   wt wt   Neg Neg 
167  wt wt  wt  wt  p.Gly12Cys   c.34G>T  Neg Neg 
168  wt wt  wt  wt   wt wt   Neg Neg 
169  wt wt  wt  wt  wt  wt   Neg Neg 
170  Neg Neg p.Leu8
58Arg 
c.257
3T>G 
 wt wt   Neg Neg 
171  wt wt  wt  wt  wt  wt   Neg Neg 
172 p.Glu746_Thr751
delinsAla 
 c.2237_2251del  Neg Neg  wt wt   Neg Neg 
173  wt wt  wt  wt  wt  wt  ND ND 
174  wt wt  wt  wt  wt  wt   Neg Neg 
175  wt wt  wt  wt  wt  wt   Neg Neg 
176  wt wt  wt  wt  p.Gly12Asp  c.35G>A ND ND 
177  wt wt  wt  wt  p.Gly12Asp  c.35G>A ND ND 
178  wt wt  wt  wt   wt wt  Neg Neg 
179  wt wt  wt  wt  p.Gly12Asp  c.35G>A ND ND 
180  wt wt  wt  wt   wt wt   Neg Neg 
181  wt wt  wt  wt   wt wt   Neg Neg 
182  wt wt  wt  wt   wt wt  ND ND 
183  wt wt  wt  wt   wt wt   Neg Neg 
184  wt wt  wt  wt  p.Gly12Asp  c.35G>A ND ND 
185  wt wt  wt  wt  wt  wt  ND ND 
186  wt wt  wt  wt  wt  wt   Neg Neg 
187  wt wt  wt  wt  p.Gly12Ser  c.34G>A  Neg Neg 
188  Neg Neg  Neg  Neg   wt wt   Neg Neg 
189  wt wt  wt  wt  p.Gly12Asp  c.35G>A ND ND 
190 p.Glu746_Ala750
del 
c.2235_2249del  Neg Neg  wt wt   Neg Neg 
191 ND ND ND ND  wt wt  ND ND 
192 wt wt wt wt  wt wt  ND ND 
193 p.Glu746_Ala750
del  
c.2235_2249del  Neg Neg  wt wt  ND ND 
194  wt wt  wt  wt  wt  wt   Neg Neg 
195  wt wt  wt  wt  wt  wt   Neg Neg 
196  wt wt  wt  wt  wt  wt   Neg Neg 
197  wt wt  wt  wt  wt  wt  ND ND 
198  wt wt  wt  wt  wt  wt   Neg Neg 
199  wt wt  wt  wt  wt  wt  ND ND 
200  wt wt  wt  wt  wt  wt  ND ND 
201  wt wt  wt  wt  wt  wt   Neg Neg 
202 wt wt ND ND  wt wt  ND ND 
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203 p.Glu746_Ala750
del 
c.2235_2249del  Neg Neg  wt wt  ND ND 
204  wt wt  wt  wt  wt  wt   Neg Neg 
205 ND ND ND ND ND ND ND ND 
206  wt wt  wt  wt  p.Gly12Asp  c.35G>A ND ND 
207 p.Glu746_Ala750
del 
c.2235_2249del  Neg Neg wt  wt   Neg Neg 
 
ND - Not Done 
Wt - Wild Type 
Neg – Negative 
  
 
